A Phase 2 interventional study of CAB LA and RPV LA in HIV Infections, sponsored by ViiV Healthcare. Completed at 30 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-06-11.
Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies testing cabotegravir in HIV Infections — 4 open to participants now, 13 under way, 8 of them phase 3. cabotegravir · HIV Infections.
Among the 36 studies testing cabotegravir in HIV Infections, this one is the 23rd largest by enrollment, is the only one that started in 2018, is one of 8 in phase 2, and was the 17th registered.
4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.
Browse HIV Infections studies →4 of the 36 studies testing cabotegravir in HIV Infections are open now, in 3 countries. Recruiting first, the newest first:
ViiV Healthcare · Sites in South Africa
Ages up to 10 days · Healthy volunteers
Africa Health Research Institute · Sites in South Africa
Ages 15–30 · Healthy volunteers
Evandro Chagas National Institute of Infectious Disease · Sites in Brazil
Ages 18–30 · Men only · Healthy volunteers
Duke University · Sites in United States
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
cabotegravir: first FDA approval 2021 (VOCABRIA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 11 · Phase 3 13 · Phase 4 3
First in 2008; this study’s year is marked. 1 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 97 is above the median of 80 across 3,492 interventional studies indexed under HIV Infections.
Median enrollment 200 across the 36 interventional studies. Of the 23 that completed or were terminated, 18 (78%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 36 have an industry lead sponsor. The 7 most frequent:
This study is registered under ViiV Healthcare, one of the names counted as GlaxoSmithKline. Under that name alone:
ViiV Healthcare is the lead sponsor of 267 studies on the registry; 18 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 53 (75%) have results posted.
266 studies in HIV Infections by GlaxoSmithKline: 15 open now, 27 under way, 8 of them phase 3. Of 230 finished, 95 (41%) have results posted.
Among the 266 studies in HIV Infections by GlaxoSmithKline, this one is the 100th largest by enrollment of the 210 interventional ones that give a count, is one of 8 that started in 2018, is one of 48 in phase 2, and was the 193rd registered.
GlaxoSmithKline’s HIV Infections studies by the year they started, since 1994.
1 of the studies testing cabotegravir in HIV Infections that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06786520ViiV HealthcareA Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Cabotegravir Ultra Long-acting (CAB ULA) Following Switch From Cabotegravir Long-acting (CAB LA) in Healthy Adults | 2027-03-08 |
Add it to your calendar (.ics) → With an account.
Among the 36 studies testing cabotegravir in HIV Infections, from their registry updates:
Among GlaxoSmithKline’s 266 in HIV Infections:
This tab as a report to print or save as PDF → With an account.
This study (POLAR), is designed to assess the antiviral activity and safety of CAB LA plus RPV LA, administered Q2M, in approximately 100 adult HIV-1 infected, antiretroviral therapy (ART) experienced participants. Participants will rollover from the NCT01641809 (LATTE) study, who have completed minimum duration of Week 312 and with demonstrated HIV-1 ribonucleic acid (RNA) suppression (less than [\<]50 copies (c) per milliliter [mL]), while receiving a two-drug regimen consisting of once-daily oral CAB at 30 milligram (mg) plus RPV at 25 mg. The participants will be offered the option to switch to the LA, intramuscular injections of CAB LA plus RPV LA, Q2M or the oral fixed dose combination (FDC) of dolutegravir (DTG) plus RPV, for the continued maintenance of HIV-1 RNA suppression, known as the Maintenance Phase (From Day 1 to Commercial Approval). Duration of study will vary from country to country, until regimen receives regulatory approval and becomes commercially available. The study plans to enroll approximately 100 participants. Any participant who receives at least one dose of CAB LA and/or RPV LA and discontinues the CAB LA plus RPV LA regimen for any reason will enter a 52-week Long-Term Follow-Up (LTFU) phase. Those participants must remain on suppressive highly active antiretroviral therapy (HAART) for at least 52 weeks after the last dose of CAB LA and or RPV LA.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
A female participant is eligible to participate if she is not pregnant (as confirmed by a negative urine human chorionic gonadotrophin [hCG] test at Day 1), not lactating, and at least with one of following conditions:
(a) Non- defined as: (i) Pre-menopausal females with one of the conditions as documented tubal ligation; Documented hysteroscopic tubal occlusion procedure with follow-up confirmation of bilateral tubal occlusion, Hysterectomy, Documented Bilateral Oophorectomy.
(ii) defined as 12 months of spontaneous amenorrhea [in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) and estradiol levels consistent with menopause (refer to laboratory reference ranges for confirmatory levels)]. Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the highly effective methods if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of post-menopausal status prior to study enrolment.
(b) Reproductive potential and agrees to follow one of the options listed in the Modified List of Highly Effective Methods for Avoiding Pregnancy in Females of Reproductive Potential (FRP) from 30 days prior to the first dose of study medication, throughout the study, for at least 30 days after discontinuation of all oral study medications, and for at least 52 weeks after discontinuation of CAB LA and RPV LA.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Eligible participants from LAI116482 (NCT01641809 \[LATTE\]) study who were administered oral CAB 30 milligrams (mg) plus RPV 25 mg and who successfully completed Week 300 received their first dose CAB LA (600 mg) plus RPV LA (900 mg) injections within 2 hours of the final oral dose of LATTE given on the same day. The second loading injections were administered 1 month after initial loading dose, with subsequent injections (CAB LA 600 mg + RPV LA 900 mg) occurring Q2M thereafter. Participants continued to receive the treatment until the study intervention was locally approved and commercially available. Participants who received at least one dose of CAB LA and/or RPV LA and discontinued the CAB LA + RPV LA regimen for any reason entered a 52-week long-term follow-up (LTFU) Phase.
Drug: CAB LA · Drug: RPV LA
Eligible participants from LAI116482 (NCT01641809 \[LATTE\]) study who were administered oral CAB 30 mg plus RPV 25 mg and who successfully completed Week 300 received their first dose of the Dolutegravir (DTG) 50 mg plus RPV 25 mg, once daily as oral regimen on Day 1 until Month 12 in the current study. These participants were not eligible for the LTFU phase.
Drug: RPV · Drug: DTG
This group included the participants who received at least one dose of CAB LA and/or RPV LA and discontinued the CAB LA + RPV LA regimen for any reason before end of Maintenance Period. The participants entered a 52-week LTFU period.
Drug: CAB LA · Drug: RPV LA
Administered CAB LA (600 mg) Q2M, as intramuscular injection.
Administered RPV LA (900 mg), Q2M, as intramuscular injection.
Oral dose of RPV 25 mg, administered once daily from Day 1 up to Month 12
Oral dose of DTG 50 mg administered once daily from Day 1 up to Month 12.
Percentage of Participants With HIV-ribonucleic Acid (RNA) >=50 Copies Per Milliliter (c/mL) as Per Food and Drug Administration (FDA) Snapshot Algorithm at Month 12 [Maintenance Phase]
Percentage of participants with HIV-1 RNA \>=50 c/mL as per FDA snapshot algorithm at Month 12 was assessed to demonstrate the antiviral activity of CAB LA+RPV LA Q2M and DTG + RPV regimen in HIV-1 infected antiretroviral therapy (ART) experienced participants. The HIV-1 RNA \>=50 c/mL per Snapshot algorithm was determined by the last on-treatment HIV-1 RNA measurement within the 12 months analysis visit window.
Time frame: At Month 12 [Maintenance Phase]
Percentage of Participants With HIV-RNA <50 c/mL as Per FDA Snapshot Algorithm at Month 12 [Maintenance Phase]
Percentage of participants with HIV-1 RNA \<50 c/mL as per FDA snapshot algorithm at Month 12 was assessed to demonstrate the antiviral activity of CAB LA+RPV LA Q2M and oral DTG + RPV regimen. The HIV-1 RNA \<50 c/mL per Snapshot algorithm was determined by the last on-treatment HIV-1 RNA measurement within the 12 months analysis visit window.
Time frame: At Month 12 [Maintenance Phase]
Number of Participants With Protocol-defined Confirmed Virologic Failure up to End of Maintenance Phase
Confirmed virologic failure was defined as rebound as indicated by two consecutive plasma HIV-1-RNA levels \>=200 c/mL after prior suppression to \<200 c/mL.
Time frame: Up to End of Maintenance Phase (up to Month 52 for CAB LA+RPV LA Q2M group, up to Month 12 for DTG+RPV group)
Percentage of Participants With HIV-RNA >=50 c/mL as Per FDA Snapshot Algorithm Over Time for CAB LA + RPV LA Q2M Arm up to Month 12 [Maintenance Phase]
Percentage of participants with HIV-1 RNA \>=50 c/mL as per FDA snapshot algorithm over time was assessed to demonstrate the antiviral activity of CAB LA+RPV LA Q2M regimen in HIV-1 infected ART experienced participants. The HIV-1 RNA \>=50 c/mL per Snapshot algorithm was determined by the last on-treatment HIV-1 RNA measurement within the 12 months analysis visit window. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.
Time frame: At Baseline (Day 1) and at Months 2, 4, 6, 8, 10 and 12 [Maintenance Phase]
Percentage of Participants With HIV-RNA >=50 c/mL as Per FDA Snapshot Algorithm Over Time for DTG + RPV up to Month 12 [Maintenance Phase]
Percentage of participants with HIV-1 RNA \>=50 c/mL as per FDA snapshot algorithm over time was assessed to demonstrate the antiviral activity of DTG + RPV regimen in HIV-1 infected ART experienced participants. The HIV-1 RNA \>=50 c/mL per Snapshot algorithm was determined by the last on-treatment HIV-1 RNA measurement within the 12 months analysis visit window. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.
Time frame: At Baseline (Day 1) and at Months 3, 6, 9 and 12 [Maintenance Phase]
Absolute Values for HIV-1 RNA of CAB LA + RPV LA Q2M Arm up to End of LTFU Phase
Plasma samples were collected for quantitative analysis of HIV-1 RNA. Logarithm to base 10 (log10) values for plasma HIV-1 RNA have been presented. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Standard Deviation (SD)=0.0000 is defined as SD resulted below the detectable limit of the assay and approximate to 0.0000.
Time frame: From Baseline (Day 1) up to End of LTFU Phase (approximately up to 12 months after exiting the Maintenance Phase)
Absolute Values for HIV-1 RNA of DTG + RPV Arm up to Month 12 [Maintenance Phase]
Plasma samples were collected for quantitative analysis of HIV-1 RNA. Logarithm to base 10 (log10) values for plasma HIV-1 RNA has been presented. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. SD=0.0000 is defined as SD resulted below the detectable limit of the assay and approximate to 0.0000.
Time frame: At Baseline (Day 1) and at Months 3, 6, 9 and 12 [Maintenance Phase]
Change From Baseline in HIV-1 RNA for CAB LA + RPV LA Q2M Arm up to End of LTFU Phase
Plasma samples were collected for quantitative analysis of HIV-1 RNA. Log 10 values for plasma HIV-1 RNA has been presented. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from baseline value is defined as post-dose value minus baseline value. SD=0.0000 is defined as SD resulted below the detectable limit of the assay and approximate to 0.0000.
Time frame: Up to End of LTFU Phase (compared with Baseline [Day1]), (approximately up to 12 months after exiting the Maintenance Phase)
Change From Baseline in HIV-1 RNA for DTG + RPV Arm up to Month 12 [Maintenance Phase]
Plasma samples were collected for quantitative analysis of HIV-1 RNA. Log 10 values for plasma HIV-1 RNA has been presented. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from baseline value is defined as post-dose value minus baseline value. SD=0.0000 is defined as SD resulted below the detectable limit of the assay and approximate to 0.0000.
Time frame: At Months 3, 6, 9 and 12 (compared with Baseline [Day 1]) [Maintenance Phase]
Absolute Values for Cluster of Differentiation 4 Plus (CD4+) for CAB LA + RPV LA Q2M Arm up to End of LTFU Phase
Blood samples were collected and CD4+ cell count assessment by flow cytometry was carried out to evaluate the immunologic activity of CAB LA+RPV LA Q2M. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.
Time frame: From Baseline (Day 1) up to End of LTFU Phase (approximately up to 12 months after exiting the Maintenance Phase)
Absolute Values for CD4+ for DTG + RPV Arm up to Month 12 [Maintenance Phase]
Blood samples were collected and CD4+ cell count assessment by flow cytometry was carried out to evaluate the immunologic activity of DTG + RPV arm. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.
Time frame: At Baseline (Day 1) and at Months 3, 6, 9 and 12 [Maintenance Phase]
Change From Baseline Values for CD4+ for CAB LA + RPV LA Q2M Arm up to End of LTFU Phase
Blood samples were collected and CD4+ cell count assessment by flow cytometry was carried out to evaluate the immunologic activity of CAB LA+RPV LA Q2M. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from baseline value is defined as post-dose value minus baseline value.
Time frame: Up to End of LTFU Phase (compared with Baseline [Day1]), (approximately up to 12 months after exiting the Maintenance Phase)
Change From Baseline Values for CD4+ for DTG + RPV Arm up to Month 12 [Maintenance Phase]
Blood samples were collected and CD4+ cell count assessment by flow cytometry was carried out to evaluate the immunologic activity of DTG + RPV arm. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from baseline value is defined as post-dose value minus baseline value.
Time frame: At Months 3, 6, 9 and 12 (compared with Baseline [Day 1]) [Maintenance Phase]
Number of Participants With Non-serious Adverse Events (Non-SAEs >=5 Percent [%] Incidence) and Serious Adverse Events (SAEs) for CAB LA + RPV LA Q2M Arm
An adverse event is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect, associated with liver injury and impaired liver function or any other situations as per medical or scientific judgement.
Time frame: Up to End of LTFU Phase (approximately up to 12 months after exiting the Maintenance Phase)
Number of Participants With Non-serious Adverse Events (Non-SAEs >=5 Percent [%] Incidence) and Serious Adverse Events (SAEs) for DTG + RPV Arm
An adverse event is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect, associated with liver injury and impaired liver function or any other situations as per medical or scientific judgement.
Time frame: Up to Month 12 [Maintenance Phase]
Number of Participants With Severity of Adverse Events for CAB LA + RPV LA Q2M Arm
Severity of adverse events were defined as per The Division of Acquired Immunodeficiency Syndrome (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS adverse events Grading Table). Severity grades for adverse events were Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe), Grade 4 (Potentially life-threatening) and Grade 5 (all deaths related to an AE).
Time frame: Up to End of LTFU Phase (approximately up to 12 months after exiting the Maintenance Phase)
Number of Participants With Severity of Adverse Events for DTG + RPV Arm
Severity of adverse events were defined as per The Division of Acquired Immunodeficiency Syndrome (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS adverse events Grading Table). Severity grades for adverse events were Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe), Grade 4 (Potentially life-threatening) and Grade 5 (all deaths related to an AE).
Time frame: Up to Month 12 [Maintenance Phase]
Number of Participants With Maximum Post-Baseline Chemistry Toxicities for CAB LA + RPV LA Q2M Arm up to End of Maintenance Phase
Clinical chemistry toxicities were graded as per the DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table). Blood samples were collected for the analysis of following clinical chemistry parameters: alanine aminotransferase (ALT), albumin, aspartate aminotransferase (AST), bilirubin, carbon dioxide (CO2), cholesterol, creatinine kinase, creatinine, direct bilirubin, glomerular filtration rate (GFR) from creatinine adjusted using chronic kidney disease epidemiology collaboration (CKD-EPI), GFR from creatinine adjusted for bovine serum albumin (BSA), glucose, low density lipoprotein (LDL) cholesterol calculation, lipase, phosphate, sodium and triglycerides. Severity grades were: Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe) and Grade 4 (Potentially life-threatening).
Time frame: Up to End of Maintenance Phase (up to Month 52)
Number of Participants With Maximum Post-Baseline Chemistry Toxicities for DTG + RPV Arm up to Month 12 [Maintenance Phase]
Clinical chemistry toxicities were graded as per the DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table). Blood samples were collected for the analysis of following clinical chemistry parameters: alanine aminotransferase (ALT), albumin, aspartate aminotransferase (AST), bilirubin, carbon dioxide (CO2), cholesterol, creatinine kinase, creatinine, direct bilirubin, glomerular filtration rate (GFR) from creatinine adjusted using chronic kidney disease epidemiology collaboration (CKD-EPI), GFR from creatinine adjusted for bovine serum albumin (BSA), glucose, low density lipoprotein (LDL) cholesterol calculation, lipase, phosphate, sodium and triglycerides. Severity grades were: Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe) and Grade 4 (Potentially life-threatening).
Time frame: Up to Month 12 [Maintenance Phase]
Number of Participants With Maximum Post-Baseline Hematology Toxicities for CAB LA + RPV LA Q2M Arm up to End of Maintenance Phase
The hematology toxicities were graded as per the DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table). Blood samples were collected for the analysis of the hematology parameter: platelets. Severity grades were: Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe) and Grade 4 (Potentially life-threatening).
Time frame: Up to End of Maintenance Phase (up to Month 52)
Number of Participants With Maximum Post-Baseline Hematology Toxicities for DTG + RPV Arm up to Month 12 [Maintenance Phase]
The hematology toxicities were graded as per the DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table). Blood samples were collected for the analysis of the hematology parameter: platelets. Severity grades were: Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe) and Grade 4 (Potentially life-threatening).
Time frame: Up to Month 12 [Maintenance Phase]
Number of Participants Who Permanently Discontinued Treatment Due to Adverse Events for CAB LA + RPV LA Q2M Arm up to End of Maintenance Phase
An adverse event is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. Number of participants with adverse events leading to permanent withdrawal has been presented.
Time frame: Up to End of Maintenance Phase (up to Month 52)
Number of Participants Who Permanently Discontinued Treatment Due to Adverse Events for DTG + RPV Arm up to Month 12 [Maintenance Phase]
An adverse event is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. Number of participants with adverse events leading to permanent withdrawal has been presented.
Time frame: Up to Month 12 [Maintenance Phase]
Change From Baseline in Clinical Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase for CAB LA + RPV LA Q2M Arm up to End of LTFU Phase
Blood samples were collected for the analysis of clinical chemical parameters including ALT, ALP, AST and creatinine kinase. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time frame: Up to End of LTFU Phase (compared with Baseline [Day1]), (approximately up to 12 months after exiting the Maintenance Phase)
Change From Baseline in Clinical Chemistry Parameters: ALT, ALP, AST and Creatinine Kinase for DTG + RPV Arm up to Month 12 [Maintenance Phase]
Blood samples were collected for the analysis of clinical chemical parameters including ALT, ALP, AST and creatinine kinase. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time frame: At Months 3, 6, 9 and 12 (compared with Baseline [Day 1]) [Maintenance Phase]
Change From Baseline in Clinical Chemistry Parameter: Albumin for CAB LA + RPV LA Q2M Arm up to LTFU Phase
Blood samples were collected for the analysis of clinical chemical parameter: albumin. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was defined as post-dose visit value minus Baseline value. SD=0.00 is defined as SD resulted below the detectable limit of the assay and approximate to 0.00.
Time frame: Up to End of LTFU Phase (compared with Baseline [Day1]), (approximately up to 12 months after exiting the Maintenance Phase)
Change From Baseline in Clinical Chemistry Parameter: Albumin for DTG+ RPV Arm up to Month 12 [Maintenance Phase]
Blood samples were collected for the analysis of clinical chemistry parameter: albumin. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline was defined as post-dose visit value minus baseline value.
Time frame: At Months 3, 6, 9 and 12 (compared with Baseline [Day 1]) [Maintenance Phase]
Change From Baseline in Clinical Chemistry Parameters: Bilirubin, Creatinine for CAB LA + RPV LA Q2M Arm up to End of LTFU Phase
Blood samples were collected for the analysis of clinical chemistry parameters: bilirubin and creatinine. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline was defined as post-dose visit value minus baseline value.
Time frame: Up to End of LTFU Phase (compared with Baseline [Day1]), (approximately up to 12 months after exiting the Maintenance Phase)
Change From Baseline in Clinical Chemistry Parameters: Bilirubin, Creatinine for DTG+ RPV Arm up to Month 12 [Maintenance Phase]
Blood samples were collected for the analysis of clinical chemistry parameters: bilirubin and creatinine. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline was defined as post-dose visit value minus baseline value.
Time frame: At Months 3, 6, 9 and 12 (compared with Baseline [Day 1]) [Maintenance Phase]
Change From Baseline in Clinical Chemistry Parameters: Carbon Dioxide, Chloride, Glucose, Phosphate, Potassium, Sodium and Urea for CAB LA + RPV LA Q2M Arm up to End of LTFU Phase
Blood samples were collected for the analysis of clinical chemistry parameters: carbon dioxide, chloride, glucose, phosphate, potassium, sodium and urea. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline was defined as post-dose visit value minus baseline value. SD=0.00(0) is defined as SD resulted below the detectable limit of the assay and approximate to 0.00(0).
Time frame: Up to End of LTFU Phase (compared with Baseline [Day1]), (approximately up to 12 months after exiting the Maintenance Phase)
Change From Baseline in Clinical Chemistry Parameters: Carbon Dioxide, Chloride, Glucose, Phosphate, Potassium, Sodium and Urea for DTG + RPV Arm up to Month 12 [Maintenance Phase]
Blood samples were collected for the analysis of clinical chemistry parameters: carbon dioxide, chloride, glucose, phosphate, potassium, sodium and urea. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline was defined as post-dose visit value minus baseline value.
Time frame: At Months 3, 6, 9 and 12 (compared with Baseline [Day 1]) [Maintenance Phase]
Change From Baseline in Clinical Chemistry Parameters: Cholesterol, High Density Lipoprotein, Cholesterol Direct, Low Density Lipoprotein Cholesterol Calculation, and Cholesterol Direct, Triglycerides for CAB LA + RPV LA Q2M Arm up to End of LTFU Phase
Blood samples were collected for the analysis of clinical chemistry parameters: cholesterol, direct high density lipoprotein cholesterol, LDL cholesterol calculation, direct low density lipoprotein cholesterol and triglycerides. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline was defined as post-dose visit value minus baseline value.
Time frame: Up to End of LTFU Phase (compared with Baseline [Day1]), (approximately up to 12 months after exiting the Maintenance Phase)
Absolute Values of Clinical Chemistry Parameters: Cholesterol, Direct HDL Cholesterol, LDL Calculation, Direct LDL Cholesterol and Triglycerides for DTG + RPV Arm at Baseline
Blood samples were collected for the analysis of clinical chemistry parameters: cholesterol, HDL cholesterol direct, LDL cholesterol calculation, LDL cholesterol direct and triglycerides.
Time frame: At Baseline (Day 1)
Change From Baseline in Clinical Chemistry Parameter: GFR From Creatinine Adjusted Using CKD-EPI for CAB LA + RPV LA Q2M Arm up to End of LTFU Phase
Blood samples were collected for the analysis of clinical chemistry parameter: GFR from creatinine adjusted using CKD-EPI. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline was defined as post-dose visit value minus baseline value.
Time frame: Up to End of LTFU Phase (compared with Baseline [Day1]), (approximately up to 12 months after exiting the Maintenance Phase)
Change From Baseline in Clinical Chemistry Parameter: GFR From Creatinine Adjusted Using CKD-EPI for DTG + RPV Arm up to Month 12 [Maintenance Phase]
Blood samples were collected for the analysis of clinical chemistry parameter: GFR from creatinine adjusted using CKD-EPI. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline was defined as post-dose visit value minus baseline value.
Time frame: At Months 3, 6, 9 and 12 (compared with Baseline [Day 1]) [Maintenance Phase]
Change From Baseline in Clinical Chemistry Parameter: GFR From Creatinine Adjusted BSA for CAB LA + RPV LA Q2M Arm up to End of LTFU Phase
Blood samples were collected for the analysis of clinical chemistry parameter: GFR from creatinine adjusted for BSA. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline was defined as post-dose visit value minus baseline value.
Time frame: Up to End of LTFU Phase (compared with Baseline [Day1]), (approximately up to 12 months after exiting the Maintenance Phase)
Change From Baseline in Clinical Chemistry Parameter: GFR From Creatinine Adjusted BSA for DTG + RPV Arm up to Month 12 [Maintenance Phase]
Blood samples were collected for the analysis of clinical chemistry parameter: GFR from creatinine adjusted for BSA. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline was defined as post-dose visit value minus baseline value.
Time frame: At Months 3, 6, 9 and 12 (compared with Baseline [Day 1]) [Maintenance Phase]
Change From Baseline in Clinical Chemistry Parameter: Lipase for CAB LA + RPV LA Q2M Arm up to End of LTFU Phase
Blood samples were collected for the analysis of clinical chemistry parameter: lipase. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline was defined as post-dose visit value minus baseline value.
Time frame: Up to End of LTFU Phase (compared with Baseline [Day1]), (approximately up to 12 months after exiting the Maintenance Phase)
Change From Baseline in Clinical Chemistry Parameter: Lipase for DTG + RPV Arm up to Month 12 [Maintenance Phase]
Blood samples were collected for the analysis of clinical chemistry parameter: lipase. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline was defined as post-dose visit value minus baseline value.
Time frame: At Months 3, 6, 9 and 12 (compared with Baseline [Day 1]) [Maintenance Phase]
Change From Baseline in Clinical Chemistry Parameter: Total Cholesterol/ HDL Cholesterol Ratio for CAB LA + RPV LA Q2M Arm up to End of LTFU Phase
Blood samples were collected for the analysis of clinical chemistry parameter: total cholesterol/ HDL cholesterol ratio. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline was defined as post-dose visit value minus baseline value.
Time frame: Up to End of LTFU Phase (compared with Baseline [Day1]), (approximately up to 12 months after exiting the Maintenance Phase)
Change From Baseline in Clinical Chemistry Parameter: Total Cholesterol/ HDL Cholesterol Ratio for DTG + RPV Arm at Month 6 [Maintenance Phase]
Blood samples were collected for the analysis of clinical chemistry parameter: total cholesterol/ HDL cholesterol ratio. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline was defined as post-dose visit value minus baseline value.
Time frame: At Month 6 (compared with Baseline [Day 1]) [Maintenance Phase]
Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils and Platelets for CAB LA + RPV LA Q2M Arm up to End of LTFU Phase
Blood samples were collected for the analysis of hematology parameters: basophils, eosinophils, leukocytes, lymphocytes, monocytes, neutrophils and platelets. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline was defined as post-dose visit value minus baseline value.
Time frame: Up to End of LTFU Phase (compared with Baseline [Day1]), (approximately up to 12 months after exiting the Maintenance Phase)
Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils and Platelets for DTG + RPV Arm up to Month 12 [Maintenance Phase]
Blood samples were collected for the analysis of hematology parameters: basophils, eosinophils, leukocytes, lymphocytes, monocytes, neutrophils and platelets. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline was defined as post-dose visit value minus baseline value.
Time frame: At Months 3, 6, 9 and 12 (compared with Baseline [Day 1]) [Maintenance Phase]
Change From Baseline in Hematology Parameter: Erythrocyte Mean Corpuscular Volume for CAB LA + RPV LA Q2M Arm up to End of LTFU Phase
Blood samples were collected for the analysis of hematology parameter: erythrocytes mean corpuscular volume. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline was defined as post-dose visit value minus baseline value.
Time frame: Up to End of LTFU Phase (compared with Baseline [Day1]), (approximately up to 12 months after exiting the Maintenance Phase)
Change From Baseline in Hematology Parameter: Erythrocyte Mean Corpuscular Volume for DTG + RPV Arm up to Month 12 [Maintenance Phase]
Blood samples were collected for the analysis of hematology parameter: erythrocytes mean corpuscular volume. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline was defined as post-dose visit value minus baseline value.
Time frame: At Months 3, 6, 9 and 12 (compared with Baseline [Day 1]) [Maintenance Phase]
Change From Baseline in Hematology Parameter: Erythrocytes for CAB LA + RPV LA Q2M Arm up to End of LTFU Phase
Blood samples were collected for the analysis of hematology parameter: erythrocytes. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline was defined as post-dose visit value minus baseline value. SD=0.0000 is defined as SD resulted below the detectable limit of the assay and approximate to 0.0000.
Time frame: Up to End of LTFU Phase (compared with Baseline [Day1]), (approximately up to 12 months after exiting the Maintenance Phase)
Change From Baseline in Hematology Parameter: Erythrocytes for DTG + RPV Arm up to Month 12 [Maintenance Phase]
Blood samples were collected for the analysis of hematology parameter: erythrocytes. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline was defined as post-dose visit value minus baseline value.
Time frame: At Months 3, 6, 9 and 12 (compared with Baseline [Day 1]) [Maintenance Phase]
Change From Baseline in Hematology Parameter: Hematocrit for CAB LA + RPV LA Q2M Arm up to End of LTFU Phase
Blood samples were collected for the analysis of hematology parameter: hematocrit. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline was defined as post-dose visit value minus baseline value.
Time frame: Up to End of LTFU Phase (compared with Baseline [Day1]), (approximately up to 12 months after exiting the Maintenance Phase)
Change From Baseline in Hematology Parameter: Hematocrit for DTG + RPV Arm up to Month 12 [Maintenance Phase]
Blood samples were collected for the analysis of hematology parameter: hematocrit. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline was defined as post-dose visit value minus baseline value.
Time frame: At Months 3, 6, 9 and 12 (compared with Baseline [Day 1]) [Maintenance Phase]
Change From Baseline in Hematology Parameter: Hemoglobin for CAB LA + RPV LA Q2M Arm up to End of LTFU Phase
Blood samples were collected for the analysis of hematology parameter: hemoglobin. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline was defined as post-dose visit value minus baseline value.
Time frame: Up to End of LTFU Phase (compared with Baseline [Day1]), (approximately up to 12 months after exiting the Maintenance Phase)
Change From Baseline in Hematology Parameter: Hemoglobin for DTG + RPV Arm up to Month 12 [Maintenance Phase]
Blood samples were collected for the analysis of hematology parameter: hemoglobin. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline was defined as post-dose visit value minus baseline value.
Time frame: At Months 3, 6, 9 and 12 (compared with Baseline [Day 1]) [Maintenance Phase]
Urine Albumin/Creatinine Ratio and Urine Protein/Creatinine Ratio
Urine samples were collected for the analysis of urine albumin/creatinine ratio and urine protein/creatinine ratio.
Time frame: At Baseline (Day 1)
Absolute Values of Urine Creatinine
Urine samples were collected for the analysis of urine creatinine.
Time frame: At Baseline (Day 1)
Absolute Values of Urine Phosphate
Urine samples were collected for the analysis of urine phosphate.
Time frame: At Baseline (Day 1)
Absolute Values of Urine Specific Gravity
Urine samples were collected for the analysis of urine specific gravity. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine.
Time frame: At Baseline (Day 1)
Absolute Values of Urine Potential of Hydrogen (pH)
Urine samples were collected for analysis of urine pH. pH is calculated on a scale of 0 to 14, values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH of less than 7 is acidic and a pH of greater than 7 is basic. Normal urine has a slightly acidic pH (5.0-6.0).
Time frame: At Baseline (Day 1)
Number of Participants With Treatment Emergent Genotypic Resistance
Plasma samples were collected and analyzed for genotypic resistance from participants who met confirmed virologic withdrawal criteria.
Time frame: Up to End of LTFU Phase (approximately up to 12 months after exiting the Maintenance Phase)
Number of Participants With Treatment Emergent Phenotypic Resistance
Plasma samples were collected and analyzed from participants who met confirmed virologic withdrawal criteria.
Time frame: Up to End of LTFU Phase (approximately up to 12 months after exiting the Maintenance Phase)
Change From Baseline in HIV Dependent Quality of Life (HIVDQoL - Self-completion Questionnaire Designed to Measure QoL in People Living With HIV)
HIVDQoL includes 2 overview items and 26 domain items. The 2 overview items: Item 1: 3(excellent) to -3(extremely bad); Higher score indicates better quality of life. Item 2: -3(very much better) to 1(worse); Lower score indicates better quality of life. The Weighted Impact Score (WIS) was calculated for the 26 domain items by multiplying impact score(IS) (-3\[maximum {max.} negative impact\] to +1\[max. positive impact\] by the corresponding importance score (3 \[very important\] to 0\[not all important\]). Average Weighted Impact (AWI) score was calculated by summing individual weighted IS and dividing by the number of domain items. The ranges of WIS and average IS were from -9(max. negative) to +3(max. positive);higher score indicates positive impact. Change from Baseline was defined as post-dose visit value minus Baseline value (latest pre-treatment assessment with a non-missing value). SD=0.00 is defined as SD resulted below the detectable limit of the assay and approximate to 0.00.
Time frame: At Months 6 and 12 (compared with Baseline [Day 1]) [Maintenance Phase]
Change From Baseline in Total Treatment Satisfaction Score of HIV Treatment Satisfaction Status Questionnaire (HIVTSQs)
HIVTSQs total treatment satisfaction score is computed with 1-11 items. Items 1-11 are summed to produce score with possible range of 0 to 66. Higher the score, greater improvement in satisfaction with treatment as compared to the past few weeks; lower score, greater the deterioration in satisfaction with treatment. A score of 0 represents no change. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline was defined as post-dose visit value minus baseline value.
Time frame: At Months 6 and 12 (compared with Baseline [Day 1]) [Maintenance Phase]
Change From Baseline in Individual Item Score of HIVTSQs
HIVTSQs is a 12 item questionnaire. The individual item scores are rated as 6 (very satisfied, convenient, flexible, etc.) to 0 (very dissatisfied, inconvenient, inflexible, etc.). Higher scores represent greater treatment satisfaction as compared to the past few weeks. Change from Baseline is defined as post-dose value minus Baseline value. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. SD=0.00 is defined as SD resulted below the detectable limit of the assay and approximate to 0.00.
Time frame: At Months 6 and 12 (compared with Baseline [Day 1]) [Maintenance Phase]
Change in Treatment Satisfaction Over Time Using the HIV Treatment Satisfaction Change Questionnaire (HIVTSQc)
HIVTSQc (change version) total treatment satisfaction score is computed with 1-11 items. Items 1-11 are summed to produce score with possible range:-33 to 33. Higher scores represent greater improvement in treatment satisfaction compared to satisfaction with treatment received during the induction phase; lower scores represented deterioration in satisfaction with treatment. A score of 0 represents no change. A maximum of 5 items can be missing, the missing scores were imputed with the mean of the completed item scores. If 6 or more items are missing, then the overall treatment satisfaction scale score was not computed and remained missing.
Time frame: At Month 12 (compared with Baseline [Day 1]) [Maintenance Phase]
Plasma Trough Concentration (Ctrough) for CAB LA
Blood samples were collected at indicated time points for pharmacokinetic analysis of CAB LA. This was a conditional secondary endpoint for which results are not available because the trough concentrations for this product are well characterized and therefore, secondary population pharmacokinetic (Pop PK) analyses were not conducted.
Time frame: Pre-dose (Day 1) and Month 12 [Maintenance Phase]
Ctrough for RPV LA
Blood samples were collected at indicated time points for pharmacokinetic analysis of RPV LA. This was a conditional secondary endpoint for which results are not available because the trough concentrations for this product are well characterized and therefore, secondary Pop PK analyses were not conducted.
Time frame: Pre-dose (Day 1) and Month 12 [Maintenance Phase]
This was a multicenter, open-label, rollover study evaluating the efficacy, safety and tolerability of long acting (LA) cabotegravir (CAB) plus LA rilpivirine (RPV) administered every 2 months (Q2M) in human immunodeficiency virus-1 (HIV-1) adult participants who were virologically suppressed and participated in study LAI116482 (NCT01641809).
| Milestone | CAB LA + RPV LA Q2M | DTG + RPV | LTFU: CAB LA+RPV LA Q2M Group |
|---|---|---|---|
| Started | 90 | 7 | 0 |
| Completed | 76 | 7 | 0 |
| Not completed | 14 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 |
| Withdrew: Adverse event | 1 | 0 | 0 |
| Withdrew: Decision by subject or proxy | 7 | 0 | 0 |
| Withdrew: Study site terminated by sponsor | 3 | 0 | 0 |
| Withdrew: Subject reached protocol-defined stopping criteria | 1 | 0 | 0 |
| Withdrew: Lack of efficacy | 1 | 0 | 0 |
| Milestone | CAB LA + RPV LA Q2M | DTG + RPV | LTFU: CAB LA+RPV LA Q2M Group |
|---|---|---|---|
| Started | 0 | 0 | 6 |
| Completed | 0 | 0 | 6 |
| Not completed | 0 | 0 | 0 |
Percentage of participants with HIV-1 RNA \>=50 c/mL as per FDA snapshot algorithm at Month 12 was assessed to demonstrate the antiviral activity of CAB LA+RPV LA Q2M and DTG + RPV regimen in HIV-1 infected antiretroviral therapy (ART) experienced participants. The HIV-1 RNA \>=50 c/mL per Snapshot algorithm was determined by the last on-treatment HIV-1 RNA measurement within the 12 months analysis visit window.
| Percentage of participants | CAB LA + RPV LA Q2M | DTG + RPV |
|---|---|---|
| Percentage of Participants With HIV-ribonucleic Acid (RNA) >=50 Copies Per Milliliter (c/mL) as Per Food and Drug Administration (FDA) Snapshot Algorithm at Month 12 [Maintenance Phase] | 0 (0.0 to 4.0) | 0 (0.0 to 41.0) |
Percentage of participants with HIV-1 RNA \<50 c/mL as per FDA snapshot algorithm at Month 12 was assessed to demonstrate the antiviral activity of CAB LA+RPV LA Q2M and oral DTG + RPV regimen. The HIV-1 RNA \<50 c/mL per Snapshot algorithm was determined by the last on-treatment HIV-1 RNA measurement within the 12 months analysis visit window.
| Percentage of participants | CAB LA + RPV LA Q2M | DTG + RPV |
|---|---|---|
| Percentage of Participants With HIV-RNA <50 c/mL as Per FDA Snapshot Algorithm at Month 12 [Maintenance Phase] | 98 (95 to 100) | 100 (59 to 100) |
Confirmed virologic failure was defined as rebound as indicated by two consecutive plasma HIV-1-RNA levels \>=200 c/mL after prior suppression to \<200 c/mL.
| Participants | CAB LA + RPV LA Q2M | DTG + RPV |
|---|---|---|
| Number of Participants With Protocol-defined Confirmed Virologic Failure up to End of Maintenance Phase | 1 | 0 |
Percentage of participants with HIV-1 RNA \>=50 c/mL as per FDA snapshot algorithm over time was assessed to demonstrate the antiviral activity of CAB LA+RPV LA Q2M regimen in HIV-1 infected ART experienced participants. The HIV-1 RNA \>=50 c/mL per Snapshot algorithm was determined by the last on-treatment HIV-1 RNA measurement within the 12 months analysis visit window. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.
| Percentage of participants | CAB LA + RPV LA Q2M |
|---|---|
| Baseline (Day 1) | 0 (0.0 to 4.0) |
| Month 2 | 0 (0.0 to 4.0) |
| Month 4 | 1 (0.0 to 3.3) |
| Month 6 | 0 (0.0 to 4.0) |
| Month 8 | 0 (0.0 to 4.0) |
| Month 10 | 0 (0.0 to 4.0) |
| Month 12 | 0 (0.0 to 4.0) |
Percentage of participants with HIV-1 RNA \>=50 c/mL as per FDA snapshot algorithm over time was assessed to demonstrate the antiviral activity of DTG + RPV regimen in HIV-1 infected ART experienced participants. The HIV-1 RNA \>=50 c/mL per Snapshot algorithm was determined by the last on-treatment HIV-1 RNA measurement within the 12 months analysis visit window. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.
| Percentage of participants | DTG + RPV |
|---|---|
| Baseline (Day 1) | 0.0 (0.0 to 41.0) |
| Month 3 | 0.0 (0.0 to 41.0) |
| Month 6 | 0.0 (0.0 to 41.0) |
| Month 9 | 0.0 (0.0 to 41.0) |
| Month 12 | 0.0 (0.0 to 41.0) |
Plasma samples were collected for quantitative analysis of HIV-1 RNA. Logarithm to base 10 (log10) values for plasma HIV-1 RNA have been presented. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Standard Deviation (SD)=0.0000 is defined as SD resulted below the detectable limit of the assay and approximate to 0.0000.
| Log 10 copies per milliliter | CAB LA + RPV LA Q2M | LTFU: CAB LA+RPV LA Q2M Group |
|---|---|---|
| Baseline (Day 1) | 1.591 ± 0.0085 | — |
| Month 2 | 1.590 ± 0.0000 | — |
| Month 4 | 1.594 ± 0.0305 | — |
| Month 6 | 1.590 ± 0.0042 | — |
| Month 8 | 1.590 ± 0.0000 | — |
| Month 10 | 1.594 ± 0.0384 | — |
| Month 12 | 1.590 ± 0.0000 | — |
| Month 14 | 1.593 ± 0.0216 | — |
| Month 16 | 1.598 ± 0.0555 | — |
| Month 18 | 1.592 ± 0.0217 | — |
| Month 20 | 1.592 ± 0.0153 | — |
| Month 22 | 1.590 ± 0.0000 | — |
| Month 24 | 1.602 ± 0.0882 | — |
| Month 26 | 1.611 ± 0.1246 | — |
| Month 28 | 1.594 ± 0.0334 | — |
| Month 30 | 1.590 ± 0.0000 | — |
| Month 32 | 1.590 ± 0.0000 | — |
| Month 34 | 1.590 ± 0.0000 | — |
| Month 36 | 1.590 ± 0.0000 | — |
| Month 38 | 1.590 ± 0.0000 | — |
| Month 40 | 1.590 ± 0.0000 | — |
| Month 42 | 1.590 ± 0.0000 | — |
| Month 44 | 1.591 ± 0.0104 | — |
| Month 46 | 1.590 ± 0.0000 | — |
| Month 48 | 1.590 ± 0.0025 | — |
| Month 50 | 1.590 ± 0.0000 | — |
| Month 52 | 1.590 ± 0.0000 | — |
| LTFU Month 1 | — | 1.852 ± 0.4338 |
| LTFU Month 3 | — | 1.590 ± 0.0000 |
| LTFU Month 6 | — | 1.590 ± 0.0000 |
| LTFU Month 9 | — | 2.027 ± 1.0696 |
| LTFU Month 12 | — | 1.616 ± 0.0581 |
Plasma samples were collected for quantitative analysis of HIV-1 RNA. Logarithm to base 10 (log10) values for plasma HIV-1 RNA has been presented. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. SD=0.0000 is defined as SD resulted below the detectable limit of the assay and approximate to 0.0000.
| Log 10 copies per milliliter | DTG + RPV |
|---|---|
| Baseline (Day 1) | 1.590 ± 0.0000 |
| Month 3 | 1.590 ± 0.0000 |
| Month 6 | 1.590 ± 0.0000 |
| Month 9 | 1.590 ± 0.0000 |
| Month 12 | 1.590 ± 0.0000 |
Plasma samples were collected for quantitative analysis of HIV-1 RNA. Log 10 values for plasma HIV-1 RNA has been presented. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from baseline value is defined as post-dose value minus baseline value. SD=0.0000 is defined as SD resulted below the detectable limit of the assay and approximate to 0.0000.
| Log 10 copies per milliliter | CAB LA + RPV LA Q2M | LTFU: CAB LA+RPV LA Q2M Group |
|---|---|---|
| Month 2 | -0.001 ± 0.0085 | — |
| Month 4 | 0.003 ± 0.0299 | — |
| Month 6 | -0.000 ± 0.0096 | — |
| Month 8 | -0.001 ± 0.0085 | — |
| Month 10 | 0.003 ± 0.0396 | — |
| Month 12 | -0.001 ± 0.0086 | — |
| Month 14 | 0.002 ± 0.0234 | — |
| Month 16 | 0.007 ± 0.0529 | — |
| Month 18 | 0.001 ± 0.0235 | — |
| Month 20 | 0.001 ± 0.0177 | — |
| Month 22 | -0.001 ± 0.0087 | — |
| Month 24 | 0.011 ± 0.0888 | — |
| Month 26 | 0.020 ± 0.1251 | — |
| Month 28 | 0.003 ± 0.0346 | — |
| Month 30 | -0.001 ± 0.0088 | — |
| Month 32 | -0.001 ± 0.0087 | — |
| Month 34 | -0.001 ± 0.0087 | — |
| Month 36 | -0.001 ± 0.0088 | — |
| Month 38 | 0.000 ± 0.0000 | — |
| Month 40 | -0.001 ± 0.0091 | — |
| Month 42 | -0.001 ± 0.0091 | — |
| Month 44 | 0.000 ± 0.0140 | — |
| Month 46 | -0.001 ± 0.0096 | — |
| Month 48 | -0.001 ± 0.0102 | — |
| Month 50 | 0.000 ± 0.0000 | — |
| Month 52 | 0.000 ± 0.0000 | — |
| LTFU Month 1 | — | 0.262 ± 0.4338 |
| LTFU Month 3 | — | 0.000 ± 0.0000 |
| LTFU Month 6 | — | 0.000 ± 0.0000 |
| LTFU Month 9 | — | 0.437 ± 1.0696 |
| LTFU Month 12 | — | 0.026 ± 0.0581 |
Plasma samples were collected for quantitative analysis of HIV-1 RNA. Log 10 values for plasma HIV-1 RNA has been presented. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from baseline value is defined as post-dose value minus baseline value. SD=0.0000 is defined as SD resulted below the detectable limit of the assay and approximate to 0.0000.
| Log 10 copies per milliliter | DTG + RPV |
|---|---|
| Month 3 | 0.000 ± 0.0000 |
| Month 6 | 0.000 ± 0.0000 |
| Month 9 | 0.000 ± 0.0000 |
| Month 12 | 0.000 ± 0.0000 |
Blood samples were collected and CD4+ cell count assessment by flow cytometry was carried out to evaluate the immunologic activity of CAB LA+RPV LA Q2M. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.
| Cells per cubic millimeter | CAB LA + RPV LA Q2M | LTFU: CAB LA+RPV LA Q2M Group |
|---|---|---|
| Baseline (Day 1) | 873.0 ± 233.37 | — |
| Month 2 | 868.1 ± 261.49 | — |
| Month 4 | 879.8 ± 280.88 | — |
| Month 6 | 1046.8 ± 435.74 | — |
| Month 8 | 857 ± 277.46 | — |
| Month 12 | 859.2 ± 283.23 | — |
| Month 16 | 917.5 ± 295.27 | — |
| Month 20 | 912.8 ± 262.40 | — |
| Month 24 | 910.3 ± 286.21 | — |
| Month 26 | 905.9 ± 274.22 | — |
| Month 28 | 867.3 ± 266.36 | — |
| Month 30 | 931.1 ± 220.94 | — |
| Month 32 | 853.7 ± 280.49 | — |
| Month 34 | 967.3 ± 300.72 | — |
| Month 36 | 865.4 ± 225.93 | — |
| Month 40 | 925.7 ± 271.70 | — |
| Month 42 | 1220.8 ± 536.73 | — |
| Month 44 | 905.7 ± 292.61 | — |
| Month 46 | 1011.0 ± 292.74 | — |
| Month 48 | 818.5 ± 291.82 | — |
| Month 50 | 755.0 ± 182.43 | — |
| Month 52 | 716.3 ± 143.21 | — |
| LTFU Month 1 | — | 837.2 ± 224.49 |
| LTFU Month 3 | — | 717.8 ± 188.88 |
| LTFU Month 6 | — | 766.5 ± 184.84 |
| LTFU Month 9 | — | 775.0 ± 293.45 |
| LTFU Month 12 | — | 954.8 ± 259.47 |
Blood samples were collected and CD4+ cell count assessment by flow cytometry was carried out to evaluate the immunologic activity of DTG + RPV arm. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.
| Cells per cubic millimeter | DTG + RPV |
|---|---|
| Baseline (Day 1) | 804.3 ± 167.73 |
| Month 3 | 780.3 ± 145.22 |
| Month 6 | 728.9 ± 147.06 |
| Month 9 | 777.0 ± 251.37 |
| Month 12 | 790.4 ± 141.80 |
Blood samples were collected and CD4+ cell count assessment by flow cytometry was carried out to evaluate the immunologic activity of CAB LA+RPV LA Q2M. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from baseline value is defined as post-dose value minus baseline value.
| Cells per cubic millimeter | CAB LA + RPV LA Q2M | LTFU: CAB LA+RPV LA Q2M Group |
|---|---|---|
| Month 2 | -4.9 ± 196.47 | — |
| Month 4 | 5.3 ± 221.68 | — |
| Month 6 | 100.2 ± 343.66 | — |
| Month 8 | -20.7 ± 218.39 | — |
| Month 12 | -19.4 ± 189.19 | — |
| Month 16 | 45.6 ± 227.11 | — |
| Month 20 | 43.8 ± 193.72 | — |
| Month 24 | 41.6 ± 224.99 | — |
| Month 26 | 4.2 ± 160.08 | — |
| Month 28 | -6.2 ± 196.62 | — |
| Month 30 | 18.1 ± 192.09 | — |
| Month 32 | -13.5 ± 215.60 | — |
| Month 34 | 15.8 ± 239.28 | — |
| Month 36 | 0.0 ± 195.92 | — |
| Month 40 | 67.1 ± 205.26 | — |
| Month 42 | 390.8 ± 406.79 | — |
| Month 44 | 31.6 ± 244.33 | — |
| Month 46 | -98.5 ± 424.97 | — |
| Month 48 | -44.2 ± 236.71 | — |
| Month 50 | -451.0 ± 485.08 | — |
| Month 52 | -23.0 ± 78.28 | — |
| LTFU Month 1 | — | -88.8 ± 156.64 |
| LTFU Month 3 | — | -97.8 ± 188.52 |
| LTFU Month 6 | — | -111.8 ± 236.26 |
| LTFU Month 9 | — | -103.3 ± 87.22 |
| LTFU Month 12 | — | 28.8 ± 209.33 |
Blood samples were collected and CD4+ cell count assessment by flow cytometry was carried out to evaluate the immunologic activity of DTG + RPV arm. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from baseline value is defined as post-dose value minus baseline value.
| Cells per cubic millimeter | DTG + RPV |
|---|---|
| Month 3 | -24.0 ± 118.40 |
| Month 6 | -75.4 ± 123.71 |
| Month 9 | -27.3 ± 150.96 |
| Month 12 | -13.9 ± 145.76 |
An adverse event is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect, associated with liver injury and impaired liver function or any other situations as per medical or scientific judgement.
| Participants | CAB LA + RPV LA Q2M |
|---|---|
| Non-SAE (>=5%) | 86 |
| SAE | 10 |
An adverse event is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect, associated with liver injury and impaired liver function or any other situations as per medical or scientific judgement.
| Participants | DTG + RPV |
|---|---|
| Non-SAE (>=5%) | 3 |
| SAE | 0 |
Severity of adverse events were defined as per The Division of Acquired Immunodeficiency Syndrome (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS adverse events Grading Table). Severity grades for adverse events were Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe), Grade 4 (Potentially life-threatening) and Grade 5 (all deaths related to an AE).
| Participants | CAB LA + RPV LA Q2M |
|---|---|
| Grade 1 | 22 |
| Grade 2 | 53 |
| Grade 3 | 10 |
| Grade 4 | 4 |
| Grade 5 | 0 |
Severity of adverse events were defined as per The Division of Acquired Immunodeficiency Syndrome (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS adverse events Grading Table). Severity grades for adverse events were Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe), Grade 4 (Potentially life-threatening) and Grade 5 (all deaths related to an AE).
| Participants | DTG + RPV |
|---|---|
| Grade 1 | 0 |
| Grade 2 | 3 |
| Grade 3 | 0 |
| Grade 4 | 0 |
| Grade 5 | 0 |
Clinical chemistry toxicities were graded as per the DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table). Blood samples were collected for the analysis of following clinical chemistry parameters: alanine aminotransferase (ALT), albumin, aspartate aminotransferase (AST), bilirubin, carbon dioxide (CO2), cholesterol, creatinine kinase, creatinine, direct bilirubin, glomerular filtration rate (GFR) from creatinine adjusted using chronic kidney disease epidemiology collaboration (CKD-EPI), GFR from creatinine adjusted for bovine serum albumin (BSA), glucose, low density lipoprotein (LDL) cholesterol calculation, lipase, phosphate, sodium and triglycerides. Severity grades were: Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe) and Grade 4 (Potentially life-threatening).
| Participants | CAB LA + RPV LA Q2M |
|---|---|
| ALT, Grade 1 | 15 |
| ALT, Grade 2 | 3 |
| ALT, Grade 3 | 3 |
| ALT, Grade 4 | 0 |
| AST, Grade 1 | 12 |
| AST, Grade 2 | 6 |
| AST, Grade 3 | 0 |
| AST, Grade 4 | 0 |
| Bilirubin, Grade 1 | 4 |
| Bilirubin, Grade 2 | 1 |
| Bilirubin, Grade 3 | 0 |
| Bilirubin, Grade 4 | 0 |
| CO2, Grade 1 | 13 |
| CO2, Grade 2 | 0 |
| CO2, Grade 3 | 0 |
| CO2, Grade 4 | 0 |
| Cholesterol, Grade 1 | 8 |
| Cholesterol, Grade 2 | 5 |
| Cholesterol, Grade 3 | 0 |
| Cholesterol, Grade 4 | 0 |
| Creatine kinase, Grade 1 | 8 |
| Creatine kinase, Grade 2 | 7 |
| Creatine kinase, Grade 3 | 6 |
| Creatine kinase, Grade 4 | 2 |
| Creatinine, Grade 1 | 3 |
| Creatinine, Grade 2 | 0 |
| Creatinine, Grade 3 | 0 |
| Creatinine, Grade 4 | 0 |
| Direct bilirubin, Grade 1 | 0 |
| Direct bilirubin, Grade 2 | 0 |
| Direct bilirubin, Grade 3 | 1 |
| Direct bilirubin, Grade 4 | 0 |
| GFR from creatinine adjusted using CKD-EPI, Grade 1 | 0 |
| GFR from creatinine adjusted using CKD-EPI, Grade 2 | 23 |
| GFR from creatinine adjusted using CKD-EPI, Grade 3 | 3 |
| GFR from creatinine adjusted using CKD-EPI, Grade 4 | 0 |
| GFR from creatinine adjusted for BSA, Grade 1 | 0 |
| GFR from creatinine adjusted for BSA, Grade 2 | 23 |
| GFR from creatinine adjusted for BSA, Grade 3 | 3 |
| GFR from creatinine adjusted for BSA, Grade 4 | 0 |
| Glucose, Grade 1 | 21 |
| Glucose, Grade 2 | 20 |
| Glucose, Grade 3 | 0 |
| Glucose, Grade 4 | 0 |
| LDL cholesterol calculation, Grade 1 | 7 |
| LDL cholesterol calculation, Grade 2 | 4 |
| LDL cholesterol calculation, Grade 3 | 1 |
| LDL cholesterol calculation, Grade 4 | 0 |
| Lipase, Grade 1 | 10 |
| Lipase, Grade 2 | 15 |
| Lipase, Grade 3 | 3 |
| Lipase, Grade 4 | 4 |
| Phosphate, Grade 1 | 14 |
| Phosphate, Grade 2 | 2 |
| Phosphate, Grade 3 | 0 |
| Phosphate, Grade 4 | 0 |
| Sodium, Grade 1 | 9 |
| Sodium, Grade 2 | 1 |
| Sodium, Grade 3 | 0 |
| Sodium, Grade 4 | 0 |
| Triglycerides, Grade 1 | 11 |
| Triglycerides, Grade 2 | 8 |
| Triglycerides, Grade 3 | 2 |
| Triglycerides, Grade 4 | 1 |
Clinical chemistry toxicities were graded as per the DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table). Blood samples were collected for the analysis of following clinical chemistry parameters: alanine aminotransferase (ALT), albumin, aspartate aminotransferase (AST), bilirubin, carbon dioxide (CO2), cholesterol, creatinine kinase, creatinine, direct bilirubin, glomerular filtration rate (GFR) from creatinine adjusted using chronic kidney disease epidemiology collaboration (CKD-EPI), GFR from creatinine adjusted for bovine serum albumin (BSA), glucose, low density lipoprotein (LDL) cholesterol calculation, lipase, phosphate, sodium and triglycerides. Severity grades were: Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe) and Grade 4 (Potentially life-threatening).
| Participants | DTG + RPV |
|---|---|
| ALT, Grade 1 | 1 |
| ALT, Grade 2 | 0 |
| ALT, Grade 3 | 0 |
| ALT, Grade 4 | 0 |
| AST, Grade 1 | 0 |
| AST, Grade 2 | 0 |
| AST, Grade 3 | 0 |
| AST, Grade 4 | 0 |
| Bilirubin, Grade 1 | 0 |
| Bilirubin, Grade 2 | 0 |
| Bilirubin, Grade 3 | 0 |
| Bilirubin, Grade 4 | 0 |
| CO2, Grade 1 | 1 |
| CO2, Grade 2 | 0 |
| CO2, Grade 3 | 0 |
| CO2, Grade 4 | 0 |
| Cholesterol, Grade 1 | 0 |
| Cholesterol, Grade 2 | 0 |
| Cholesterol, Grade 3 | 0 |
| Cholesterol, Grade 4 | 0 |
| Creatine kinase, Grade 1 | 0 |
| Creatine kinase, Grade 2 | 0 |
| Creatine kinase, Grade 3 | 0 |
| Creatine kinase, Grade 4 | 0 |
| Creatinine, Grade 1 | 0 |
| Creatinine, Grade 2 | 0 |
| Creatinine, Grade 3 | 0 |
| Creatinine, Grade 4 | 0 |
| Direct bilirubin, Grade 1 | 0 |
| Direct bilirubin, Grade 2 | 0 |
| Direct bilirubin, Grade 3 | 0 |
| Direct bilirubin, Grade 4 | 0 |
| GFR from creatinine adjusted using CKD-EPI, Grade 1 | 0 |
| GFR from creatinine adjusted using CKD-EPI, Grade 2 | 5 |
| GFR from creatinine adjusted using CKD-EPI, Grade 3 | 1 |
| GFR from creatinine adjusted using CKD-EPI, Grade 4 | 0 |
| GFR from creatinine adjusted for BSA, Grade 1 | 0 |
| GFR from creatinine adjusted for BSA, Grade 2 | 5 |
| GFR from creatinine adjusted for BSA, Grade 3 | 1 |
| GFR from creatinine adjusted for BSA, Grade 4 | 0 |
| Glucose, Grade 1 | 1 |
| Glucose, Grade 2 | 0 |
| Glucose, Grade 3 | 0 |
| Glucose, Grade 4 | 0 |
| LDL cholesterol calculation, Grade 1 | 0 |
| LDL cholesterol calculation, Grade 2 | 0 |
| LDL cholesterol calculation, Grade 3 | 0 |
| LDL cholesterol calculation, Grade 4 | 0 |
| Lipase, Grade 1 | 0 |
| Lipase, Grade 2 | 2 |
| Lipase, Grade 3 | 0 |
| Lipase, Grade 4 | 0 |
| Phosphate, Grade 1 | 0 |
| Phosphate, Grade 2 | 0 |
| Phosphate, Grade 3 | 0 |
| Phosphate, Grade 4 | 0 |
| Sodium, Grade 1 | 0 |
| Sodium, Grade 2 | 0 |
| Sodium, Grade 3 | 0 |
| Sodium, Grade 4 | 0 |
| Triglycerides, Grade 1 | 0 |
| Triglycerides, Grade 2 | 0 |
| Triglycerides, Grade 3 | 0 |
| Triglycerides, Grade 4 | 0 |
The hematology toxicities were graded as per the DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table). Blood samples were collected for the analysis of the hematology parameter: platelets. Severity grades were: Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe) and Grade 4 (Potentially life-threatening).
| Participants | CAB LA + RPV LA Q2M |
|---|---|
| Platelets, Grade 1 | 2 |
| Platelets, Grade 2 | 0 |
| Platelets, Grade 3 | 0 |
| Platelets, Grade 4 | 0 |
The hematology toxicities were graded as per the DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table). Blood samples were collected for the analysis of the hematology parameter: platelets. Severity grades were: Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe) and Grade 4 (Potentially life-threatening).
| Participants | DTG + RPV |
|---|---|
| Platelets, Grade 1 | 0 |
| Platelets, Grade 2 | 0 |
| Platelets, Grade 3 | 0 |
| Platelets, Grade 4 | 0 |
An adverse event is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. Number of participants with adverse events leading to permanent withdrawal has been presented.
| Participants | CAB LA + RPV LA Q2M |
|---|---|
| Number of Participants Who Permanently Discontinued Treatment Due to Adverse Events for CAB LA + RPV LA Q2M Arm up to End of Maintenance Phase | 1 |
An adverse event is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. Number of participants with adverse events leading to permanent withdrawal has been presented.
| Participants | DTG + RPV |
|---|---|
| Number of Participants Who Permanently Discontinued Treatment Due to Adverse Events for DTG + RPV Arm up to Month 12 [Maintenance Phase] | 0 |
Blood samples were collected for the analysis of clinical chemical parameters including ALT, ALP, AST and creatinine kinase. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was defined as post-dose visit value minus Baseline value.
| International units per liter | CAB LA + RPV LA Q2M | LTFU: CAB LA+RPV LA Q2M Group |
|---|---|---|
| ALT, Month 2 | -1.1 ± 16.99 | — |
| ALT, Month 4 | -1.0 ± 26.15 | — |
| ALT, Month 8 | 0.0 ± 29.86 | — |
| ALT, Month 12 | 4.0 ± 44.62 | — |
| ALT, Month 14 | -7.5 ± 61.52 | — |
| ALT, Month 16 | -2.5 ± 24.07 | — |
| ALT, Month 20 | -3.4 ± 18.61 | — |
| ALT, Month 24 | -3.0 ± 17.53 | — |
| ALT, Month 26 | -21.7 ± 49.26 | — |
| ALT, Month 28 | 1.0 ± 31.18 | — |
| ALT, Month 30 | 11.2 ± 49.09 | — |
| ALT, Month 32 | -0.9 ± 18.02 | — |
| ALT, Month 34 | -7.0 ± 30.17 | — |
| ALT, Month 36 | 0.2 ± 18.90 | — |
| ALT, Month 38 | 2.5 ± 4.95 | — |
| ALT, Month 40 | -1.7 ± 19.97 | — |
| ALT, Month 42 | -1.5 ± 6.36 | — |
| ALT, Month 44 | -0.5 ± 14.51 | — |
| ALT, Month 46 | 0.5 ± 3.79 | — |
| ALT, Month 48 | -2.6 ± 11.38 | — |
| ALT, Month 50 | -4.5 ± 7.78 | — |
| ALT, Month 52 | -3.5 ± 13.62 | — |
| ALT, LTFU Month 1 | — | -5.0 ± 7.07 |
| ALT, LTFU Month 3 | — | 2.8 ± 29.93 |
| ALT, LTFU Month 6 | — | -7.7 ± 48.87 |
| ALT, LTFU Month 9 | — | -6.0 ± 15.17 |
| ALT, LTFU Month 12 | — | 0.2 ± 54.36 |
| ALP, Month 2 | 0.2 ± 8.29 | — |
| ALP, Month 4 | 0.2 ± 14.20 | — |
| ALP, Month 8 | 2.0 ± 11.58 | — |
| ALP, Month 12 | 2.1 ± 12.39 | — |
| ALP, Month 14 | -15.5 ± 33.23 | — |
| ALP, Month 16 | 1.7 ± 10.83 | — |
| ALP, Month 20 | 5.5 ± 11.50 | — |
| ALP, Month 24 | 2.3 ± 12.64 | — |
| ALP, Month 26 | -2.2 ± 23.09 | — |
| ALP, Month 28 | 1.0 ± 12.89 | — |
| ALP, Month 30 | 2.3 ± 19.06 | — |
| ALP, Month 32 | 2.4 ± 11.79 | — |
| ALP, Month 34 | 0.4 ± 10.26 | — |
| ALP, Month 36 | 3.3 ± 9.81 | — |
| ALP, Month 38 | -10.0 ± 14.14 | — |
| ALP, Month 40 | 5.7 ± 14.32 | — |
| ALP, Month 42 | 7.0 ± 2.83 | — |
| ALP, Month 44 | 5.3 ± 16.34 | — |
| ALP, Month 46 | 1.8 ± 7.89 | — |
| ALP, Month 48 | 3.3 ± 12.21 | — |
| ALP, Month 50 | 10.5 ± 2.12 | — |
| ALP, Month 52 | -2.5 ± 7.12 | — |
| ALP, LTFU Month 1 | — | -3.6 ± 19.24 |
| ALP, LTFU Month 3 | — | -10.3 ± 23.91 |
| ALP, LTFU Month 6 | — | -5.0 ± 24.71 |
| ALP, LTFU Month 9 | — | -5.7 ± 18.28 |
| ALP, LTFU Month 12 | — | 0.0 ± 26.31 |
| AST, Month 2 | -5.6 ± 47.9 | — |
| AST, Month 4 | -5.0 ± 50.5 | — |
| AST, Month 8 | -5.3 ± 49.56 | — |
| AST, Month 12 | -2.7 ± 54.93 | — |
| AST, Month 14 | 0.0 ± 16.97 | — |
| AST, Month 16 | -5.1 ± 51.27 | — |
| AST, Month 20 | -7.5 ± 49.83 | — |
| AST, Month 24 | -7.2 ± 50.49 | — |
| AST, Month 26 | -11.5 ± 15.35 | — |
| AST, Month 28 | -7.3 ± 57.53 | — |
| AST, Month 30 | 3.3 ± 29.38 | — |
| AST, Month 32 | -6.7 ± 51.96 | — |
| AST, Month 34 | -6.4 ± 16.56 | — |
| AST, Month 36 | -5.0 ± 54.45 | — |
| AST, Month 38 | -2.0 ± 7.07 | — |
| AST, Month 40 | -8.4 ± 52.46 | — |
| AST, Month 42 | -0.5 ± 3.54 | — |
| AST, Month 44 | -2.0 ± 9.01 | — |
| AST, Month 46 | -4.3 ± 3.59 | — |
| AST, Month 48 | -3.0 ± 8.02 | — |
| AST, Month 50 | -4.5 ± 3.54 | — |
| AST, Month 52 | -6.0 ± 7.90 | — |
| AST, LTFU Month 1 | — | 3.6 ± 18.68 |
| AST, LTFU Month 3 | — | 8.5 ± 4.51 |
| AST, LTFU Month 6 | — | 1.5 ± 12.82 |
| AST, LTFU Month 9 | — | 1.5 ± 6.86 |
| AST, LTFU Month 12 | — | 14.6 ± 41.38 |
| Creatine kinase, Month 2 | -255.2 ± 2327.32 | — |
| Creatine kinase, Month 4 | -204.0 ± 2483.41 | — |
| Creatine kinase, Month 8 | -237.0 ± 2362.99 | — |
| Creatine kinase, Month 12 | -252.0 ± 2429.86 | — |
| Creatine kinase, Month 14 | 120.0 ± NA | — |
| Creatine kinase, Month 16 | -245.1 ± 2421.43 | — |
| Creatine kinase, Month 20 | -292.8 ± 2390.38 | — |
| Creatine kinase, Month 24 | -290.0 ± 2435.94 | — |
| Creatine kinase, Month 26 | -44.0 ± 115.53 | — |
| Creatine kinase, Month 28 | -393.7 ± 2738.54 | — |
| Creatine kinase, Month 30 | -33.2 ± 238.35 | — |
| Creatine kinase, Month 32 | -276.7 ± 2518.73 | — |
| Creatine kinase, Month 34 | -17.0 ± 173.27 | — |
| Creatine kinase, Month 36 | -318.6 ± 2488.91 | — |
| Creatine kinase, Month 38 | -21.0 ± 32.53 | — |
| Creatine kinase, Month 40 | -341.7 ± 2552.60 | — |
| Creatine kinase, Month 42 | 30.5 ± 31.82 | — |
| Creatine kinase, Month 44 | -15.9 ± 463.41 | — |
| Creatine kinase, Month 46 | 6.0 ± 50.28 | — |
| Creatine kinase, Month 48 | 1.0 ± 140.26 | — |
| Creatine kinase, Month 50 | -136.5 ± 178.90 | — |
| Creatine kinase, Month 52 | -67.7 ± 84.29 | — |
| Creatine kinase, LTFU Month 1 | — | -18.0 ± 21.76 |
| Creatine kinase, LTFU Month 3 | — | 81.3 ± 245.69 |
| Creatine kinase, LTFU Month 6 | — | 50.8 ± 157.89 |
| Creatine kinase, LTFU Month 9 | — | -8.8 ± 88.04 |
| Creatine kinase, LTFU Month 12 | — | 844.2 ± 1731.52 |
Blood samples were collected for the analysis of clinical chemical parameters including ALT, ALP, AST and creatinine kinase. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was defined as post-dose visit value minus Baseline value.
| International units per liter | DTG + RPV |
|---|---|
| ALT, Month 3 | -0.7 ± 22.37 |
| ALT, Month 6 | -4.3 ± 19.99 |
| ALT, Month 9 | 1.7 ± 8.16 |
| ALT, Month 12 | -0.3 ± 32.32 |
| ALP, Month 3 | 1.4 ± 10.11 |
| ALP, Month 6 | 1.6 ± 8.04 |
| ALP, Month 9 | -1.1 ± 11.74 |
| ALP, Month 12 | 10.0 ± 33.16 |
| AST, Month 3 | -0.6 ± 10.61 |
| AST, Month 6 | -3.3 ± 7.30 |
| AST, Month 9 | -1.4 ± 6.68 |
| AST, Month 12 | -0.6 ± 14.68 |
| Creatine kinase, Month 3 | -66.6 ± 287.66 |
| Creatine kinase, Month 6 | -107.9 ± 112.18 |
| Creatine kinase, Month 9 | -90.6 ± 163.40 |
| Creatine kinase, Month 12 | -134.0 ± 149.59 |
Blood samples were collected for the analysis of clinical chemical parameter: albumin. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was defined as post-dose visit value minus Baseline value. SD=0.00 is defined as SD resulted below the detectable limit of the assay and approximate to 0.00.
| Grams per liter | CAB LA + RPV LA Q2M | LTFU: CAB LA+RPV LA Q2M Group |
|---|---|---|
| Month 2 | -0.8 ± 2.31 | — |
| Month 4 | -0.9 ± 2.46 | — |
| Month 8 | -0.8 ± 2.63 | — |
| Month 12 | -0.9 ± 2.67 | — |
| Month 14 | 2.0 ± NA | — |
| Month 16 | -0.7 ± 2.81 | — |
| Month 20 | -0.3 ± 2.47 | — |
| Month 24 | -0.8 ± 2.98 | — |
| Month 26 | 0.8 ± 2.56 | — |
| Month 28 | -1.1 ± 2.68 | — |
| Month 30 | -0.3 ± 1.51 | — |
| Month 32 | -1.2 ± 2.69 | — |
| Month 34 | -0.8 ± 2.68 | — |
| Month 36 | -1.1 ± 2.80 | — |
| Month 38 | -1.0 ± 1.41 | — |
| Month 40 | -0.9 ± 3.00 | — |
| Month 42 | -3.0 ± 0.00 | — |
| Month 44 | -0.9 ± 2.50 | — |
| Month 46 | -3.3 ± 3.50 | — |
| Month 48 | -1.4 ± 2.56 | — |
| Month 50 | -2.5 ± 2.12 | — |
| Month 52 | -1.0 ± 2.00 | — |
| LTFU Month 1 | — | -3.4 ± 2.88 |
| LTFU Month 3 | — | -1.5 ± 1.29 |
| LTFU Month 6 | — | -3.0 ± 3.22 |
| LTFU Month 9 | — | -2.8 ± 3.06 |
| LTFU Month 12 | — | -3.2 ± 2.05 |
Blood samples were collected for the analysis of clinical chemistry parameter: albumin. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline was defined as post-dose visit value minus baseline value.
| Grams per liter | DTG + RPV |
|---|---|
| Month 3 | -1.6 ± 3.87 |
| Month 6 | -1.4 ± 2.30 |
| Month 9 | -1.3 ± 2.63 |
| Month 12 | -2.6 ± 2.37 |
Blood samples were collected for the analysis of clinical chemistry parameters: bilirubin and creatinine. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline was defined as post-dose visit value minus baseline value.
| Micromoles per liter | CAB LA + RPV LA Q2M | LTFU: CAB LA+RPV LA Q2M Group |
|---|---|---|
| Bilirubin, Month 2 | -1.0 ± 4.33 | — |
| Bilirubin, Month 4 | -1.0 ± 5.14 | — |
| Bilirubin, Month 8 | -1.0 ± 4.83 | — |
| Bilirubin, Month 12 | -0.5 ± 4.35 | — |
| Bilirubin, Month 14 | 2.0 ± 8.49 | — |
| Bilirubin, Month 16 | -1.0 ± 4.99 | — |
| Bilirubin, Month 20 | -1.4 ± 3.76 | — |
| Bilirubin, Month 24 | -0.8 ± 5.16 | — |
| Bilirubin, Month 26 | 0.0 ± 4.56 | — |
| Bilirubin, Month 28 | -0.9 ± 3.36 | — |
| Bilirubin, Month 30 | 2.0 ± 3.58 | — |
| Bilirubin, Month 32 | -1.0 ± 5.40 | — |
| Bilirubin, Month 34 | 0.0 ± 7.07 | — |
| Bilirubin, Month 36 | -0.4 ± 4.02 | — |
| Bilirubin, Month 38 | -2.0 ± 2.83 | — |
| Bilirubin, Month 40 | -1.6 ± 4.87 | — |
| Bilirubin, Month 42 | -1.0 ± 4.24 | — |
| Bilirubin, Month 44 | -0.9 ± 4.36 | — |
| Bilirubin, Month 46 | -3.5 ± 2.52 | — |
| Bilirubin, Month 48 | -1.7 ± 3.92 | — |
| Bilirubin, Month 50 | 1.0 ± 1.41 | — |
| Bilirubin, Month 52 | -1.3 ± 4.68 | — |
| Bilirubin, LTFU Month 1 | — | -3.2 ± 5.76 |
| Bilirubin, LTFU Month 3 | — | 1.5 ± 7.72 |
| Bilirubin, LTFU Month 6 | — | 1.3 ± 9.27 |
| Bilirubin, LTFU Month 9 | — | 1.0 ± 9.10 |
| Bilirubin, LTFU Month 12 | — | -0.8 ± 6.10 |
| Creatinine, Month 2 | -1.84 ± 7.121 | — |
| Creatinine, Month 4 | -1.70 ± 9.393 | — |
| Creatinine, Month 8 | -0.98 ± 7.977 | — |
| Creatinine, Month 10 | -1.14 ± 9.204 | — |
| Creatinine, Month 14 | -1.80 ± NA | — |
| Creatinine, Month 16 | 1.15 ± 9.508 | — |
| Creatinine, Month 20 | -0.50 ± 9.569 | — |
| Creatinine, Month 24 | 3.57 ± 10.039 | — |
| Creatinine, Month 26 | 1.03 ± 9.423 | — |
| Creatinine, Month 28 | 4.64 ± 10.159 | — |
| Creatinine, Month 30 | 9.87 ± 8.190 | — |
| Creatinine, Month 32 | 1.07 ± 9.648 | — |
| Creatinine, Month 34 | 1.06 ± 8.331 | — |
| Creatinine, Month 36 | 0.76 ± 9.661 | — |
| Creatinine, Month 38 | 0.27 ± 4.007 | — |
| Creatinine, Month 40 | -2.71 ± 8.065 | — |
| Creatinine, Month 42 | 4.73 ± 7.524 | — |
| Creatinine, Month 44 | 0.11 ± 11.223 | — |
| Creatinine, Month 46 | 8.63 ± 13.822 | — |
| Creatinine, Month 48 | 0.01 ± 9.828 | — |
| Creatinine, Month 50 | -3.50 ± 4.950 | — |
| Creatinine, Month 52 | -2.50 ± 16.393 | — |
| Creatinine, LTFU Month 1 | — | 3.00 ± 12.761 |
| Creatinine, LTFU Month 3 | — | 13.48 ± 9.469 |
| Creatinine, LTFU Month 6 | — | 8.42 ± 12.726 |
| Creatinine, LTFU Month 9 | — | 6.65 ± 7.731 |
| Creatinine, LTFU Month 12 | — | 9.74 ± 7.416 |
Blood samples were collected for the analysis of clinical chemistry parameters: bilirubin and creatinine. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline was defined as post-dose visit value minus baseline value.
| Micromoles per liter | DTG + RPV |
|---|---|
| Bilirubin, Month 3 | -1.7 ± 4.23 |
| Bilirubin, Month 6 | -1.4 ± 3.21 |
| Bilirubin, Month 9 | -0.9 ± 2.54 |
| Bilirubin, Month 12 | -1.4 ± 3.78 |
| Creatinine, Month 3 | 11.89 ± 8.89 |
| Creatinine, Month 6 | 8.36 ± 4.419 |
| Creatinine, Month 9 | 16.56 ± 10.131 |
| Creatinine, Month 12 | 7.47 ± 7.328 |
Blood samples were collected for the analysis of clinical chemistry parameters: carbon dioxide, chloride, glucose, phosphate, potassium, sodium and urea. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline was defined as post-dose visit value minus baseline value. SD=0.00(0) is defined as SD resulted below the detectable limit of the assay and approximate to 0.00(0).
| Millimoles per liter | CAB LA + RPV LA Q2M | LTFU: CAB LA+RPV LA Q2M Group |
|---|---|---|
| Carbon dioxide, Month 2 | -0.4 ± 1.86 | — |
| Carbon dioxide, Month 4 | -0.1 ± 2.00 | — |
| Carbon dioxide, Month 8 | -0.2 ± 2.22 | — |
| Carbon dioxide, Month 12 | -0.7 ± 2.18 | — |
| Carbon dioxide, Month 14 | 2.0 ± NA | — |
| Carbon dioxide, Month 16 | 0.3 ± 2.25 | — |
| Carbon dioxide, Month 20 | -0.2 ± 2.17 | — |
| Carbon dioxide, Month 24 | -0.6 ± 2.12 | — |
| Carbon dioxide, Month 26 | 1.7 ± 3.27 | — |
| Carbon dioxide, Month 28 | 0.3 ± 2.61 | — |
| Carbon dioxide, Month 30 | 1.7 ± 2.73 | — |
| Carbon dioxide, Month 32 | 0.4 ± 2.43 | — |
| Carbon dioxide, Month 34 | 0.4 ± 3.13 | — |
| Carbon dioxide, Month 36 | 0.5 ± 2.46 | — |
| Carbon dioxide, Month 38 | 1.0 ± 1.41 | — |
| Carbon dioxide, Month 40 | 1.1 ± 2.63 | — |
| Carbon dioxide, Month 42 | 0.5 ± 0.71 | — |
| Carbon dioxide, Month 44 | 0.7 ± 2.61 | — |
| Carbon dioxide, Month 46 | 0.0 ± 3.74 | — |
| Carbon dioxide, Month 48 | 0.4 ± 2.25 | — |
| Carbon dioxide, Month 50 | 1.0 ± 2.83 | — |
| Carbon dioxide, Month 52 | 1.3 ± 4.32 | — |
| Carbon dioxide, LTFU Month 1 | — | 1.0 ± 3.39 |
| Carbon dioxide, LTFU Month 3 | — | 1.5 ± 2.52 |
| Carbon dioxide, LTFU Month 6 | — | 0.7 ± 2.58 |
| Carbon dioxide, LTFU Month 9 | — | 1.0 ± 2.97 |
| Carbon dioxide, LTFU Month 12 | — | 0.2 ± 2.28 |
| Chloride, Month 2 | 1.0 ± 2.06 | — |
| Chloride, Month 4 | 1.1 ± 2.20 | — |
| Chloride, Month 8 | 1.2 ± 2.07 | — |
| Chloride, Month 12 | 1.0 ± 2.24 | — |
| Chloride, Month 14 | -5.0 ± NA | — |
| Chloride, Month 16 | 0.3 ± 2.27 | — |
| Chloride, Month 20 | 0.5 ± 2.52 | — |
| Chloride, Month 24 | 0.3 ± 2.56 | — |
| Chloride, Month 26 | -2.5 ± 1.97 | — |
| Chloride, Month 28 | -0.3 ± 2.42 | — |
| Chloride, Month 30 | -1.7 ± 2.42 | — |
| Chloride, Month 32 | -0.4 ± 2.31 | — |
| Chloride, Month 34 | -1.8 ± 2.28 | — |
| Chloride, Month 36 | -0.5 ± 2.24 | — |
| Chloride, Month 38 | 1.0 ± 0.00 | — |
| Chloride, Month 40 | -0.1 ± 2.40 | — |
| Chloride, Month 42 | -2.0 ± 4.24 | — |
| Chloride, Month 44 | 0.1 ± 2.18 | — |
| Chloride, Month 46 | 0.5 ± 2.65 | — |
| Chloride, Month 48 | -0.3 ± 2.31 | — |
| Chloride, Month 50 | 0.0 ± 1.41 | — |
| Chloride, Month 52 | -0.2 ± 2.32 | — |
| Chloride, LTFU Month 1 | — | 0.6 ± 3.91 |
| Chloride, LTFU Month 3 | — | -1.8 ± 3.30 |
| Chloride, LTFU Month 6 | — | 0.2 ± 2.32 |
| Chloride, LTFU Month 9 | — | 0.8 ± 2.14 |
| Chloride, LTFU Month 12 | — | -0.2 ± 2.28 |
| Glucose, Month 2 | 0.32 ± 0.568 | — |
| Glucose, Month 4 | 0.42 ± 0.684 | — |
| Glucose, Month 8 | 0.47 ± 0.842 | — |
| Glucose, Month 12 | 0.32 ± 0.662 | — |
| Glucose, Month 14 | -1.60 ± NA | — |
| Glucose, Month 16 | 0.36 ± 0.754 | — |
| Glucose, Month 20 | 0.33 ± 0.838 | — |
| Glucose, Month 24 | 0.19 ± 0.654 | — |
| Glucose, Month 26 | -0.17 ± 1.457 | — |
| Glucose, Month 28 | 0.30 ± 0.694 | — |
| Glucose, Month 30 | -0.36 ± 0.709 | — |
| Glucose, Month 32 | 0.34 ± 0.792 | — |
| Glucose, Month 34 | 0.95 ± 2.475 | — |
| Glucose, Month 36 | 0.26 ± 0.770 | — |
| Glucose, Month 38 | 0.20 ± 0.566 | — |
| Glucose, Month 40 | 0.25 ± 0.929 | — |
| Glucose, Month 42 | 0.20 ± NA | — |
| Glucose, Month 44 | 0.54 ± 1.044 | — |
| Glucose, Month 46 | 0.40 ± 0.265 | — |
| Glucose, Month 48 | 0.12 ± 0.593 | — |
| Glucose, Month 50 | 0.40 ± 0.283 | — |
| Glucose, Month 52 | 2.10 ± NA | — |
| Glucose, LTFU Month 1 | — | -0.37 ± 0.058 |
| Glucose, LTFU Month 3 | — | -0.45 ± 0.354 |
| Glucose, LTFU Month 6 | — | -0.40 ± 0.627 |
| Glucose, LTFU Month 9 | — | 0.02 ± 0.259 |
| Glucose, LTFU Month 12 | — | -0.12 ± 0.084 |
| Phosphate, Month 2 | -0.00 ± 0.176 | — |
| Phosphate, Month 4 | -0.00 ± 0.191 | — |
| Phosphate, Month 8 | -0.02 ± 0.206 | — |
| Phosphate, Month 12 | -0.02 ± 0.199 | — |
| Phosphate, Month 14 | 0.25 ± NA | — |
| Phosphate, Month 16 | -0.02 ± 0.199 | — |
| Phosphate, Month 20 | -0.00 ± 0.227 | — |
| Phosphate, Month 24 | -0.01 ± 0.198 | — |
| Phosphate, Month 26 | -0.14 ± 0.206 | — |
| Phosphate, Month 28 | -0.05 ± 0.216 | — |
| Phosphate, Month 30 | 0.05 ± 0.268 | — |
| Phosphate, Month 32 | -0.02 ± 0.186 | — |
| Phosphate, Month 34 | -0.02 ± 0.270 | — |
| Phosphate, Month 36 | -0.01 ± 0.192 | — |
| Phosphate, Month 38 | -0.30 ± 0.212 | — |
| Phosphate, Month 40 | 0.00 ± 0.214 | — |
| Phosphate, Month 42 | 0.10 ± 0.070 | — |
| Phosphate, Month 44 | 0.00 ± 0.201 | — |
| Phosphate, Month 46 | 0.02 ± 0.125 | — |
| Phosphate, Month 48 | 0.01 ± 0.192 | — |
| Phosphate, Month 50 | -0.20 ± 0.141 | — |
| Phosphate, Month 52 | -0.22 ± 0.216 | — |
| Phosphate, LTFU Month 1 | — | -0.03 ± 0.222 |
| Phosphate, LTFU Month 3 | — | 0.11 ± 0.225 |
| Phosphate, LTFU Month 6 | — | -0.02 ± 0.175 |
| Phosphate, LTFU Month 9 | — | -0.05 ± 0.165 |
| Phosphate, LTFU Month 12 | — | 0.11 ± 0.143 |
| Potassium, Month 2 | 0.06 ± 0.392 | — |
| Potassium, Month 4 | -0.02 ± 0.450 | — |
| Potassium, Month 8 | 0.05 ± 0.408 | — |
| Potassium, Month 12 | 0.06 ± 0.375 | — |
| Potassium, Month 14 | 0.00 ± NA | — |
| Potassium, Month 16 | 0.00 ± 0.339 | — |
| Potassium, Month 20 | 0.01 ± 0.374 | — |
| Potassium, Month 24 | -0.04 ± 0.384 | — |
| Potassium, Month 26 | 0.10 ± 0.228 | — |
| Potassium, Month 28 | -0.09 ± 0.388 | — |
| Potassium, Month 30 | 0.08 ± 0.293 | — |
| Potassium, Month 32 | 0.00 ± 0.432 | — |
| Potassium, Month 34 | 0.18 ± 0.370 | — |
| Potassium, Month 36 | -0.06 ± 0.411 | — |
| Potassium, Month 38 | 0.35 ± 0.354 | — |
| Potassium, Month 40 | -0.06 ± 0.420 | — |
| Potassium, Month 42 | -0.10 ± 0.424 | — |
| Potassium, Month 44 | -0.04 ± 0.406 | — |
| Potassium, Month 46 | -0.20 ± 0.455 | — |
| Potassium, Month 48 | -0.01 ± 0.374 | — |
| Potassium, Month 50 | 0.00 ± 0.000 | — |
| Potassium, Month 52 | 0.17 ± 0.589 | — |
| Potassium, LTFU Month 1 | — | 0.04 ± 0.313 |
| Potassium, LTFU Month 3 | — | 0.10 ± 0.606 |
| Potassium, LTFU Month 6 | — | 0.13 ± 0.501 |
| Potassium, LTFU Month 9 | — | 0.17 ± 0.873 |
| Potassium, LTFU Month 12 | — | 0.10 ± 0.212 |
| Sodium, Month 2 | 0.2 ± 1.84 | — |
| Sodium, Month 4 | 0.6 ± 2.10 | — |
| Sodium, Month 8 | 0.6 ± 1.96 | — |
| Sodium, Month 12 | 0.2 ± 1.88 | — |
| Sodium, Month 14 | -3.0 ± NA | — |
| Sodium, Month 16 | 0.5 ± 2.02 | — |
| Sodium, Month 20 | 0.4 ± 1.96 | — |
| Sodium, Month 24 | 0.5 ± 1.84 | — |
| Sodium, Month 26 | 0.2 ± 2.32 | — |
| Sodium, Month 28 | 0.3 ± 2.12 | — |
| Sodium, Month 30 | -0.8 ± 2.14 | — |
| Sodium, Month 32 | 0.4 ± 2.09 | — |
| Sodium, Month 34 | -0.6 ± 4.72 | — |
| Sodium, Month 36 | -0.1 ± 2.26 | — |
| Sodium, Month 38 | 1.0 ± 0.00 | — |
| Sodium, Month 40 | -0.1 ± 2.11 | — |
| Sodium, Month 42 | -1.0 ± 1.41 | — |
| Sodium, Month 44 | 0.2 ± 2.35 | — |
| Sodium, Month 46 | 0.0 ± 2.94 | — |
| Sodium, Month 48 | 0.1 ± 1.86 | — |
| Sodium, Month 50 | 1.0 ± 1.41 | — |
| Sodium, Month 52 | 2.5 ± 3.15 | — |
| Sodium, LTFU Month 1 | — | 1.0 ± 1.22 |
| Sodium, LTFU Month 3 | — | -0.5 ± 1.91 |
| Sodium, LTFU Month 6 | — | 0.2 ± 0.75 |
| Sodium, LTFU Month 9 | — | 0.2 ± 0.75 |
| Sodium, LTFU Month 12 | — | -0.4 ± 0.89 |
| Urea, Month 2 | 0.13 ± 1.253 | — |
| Urea, Month 4 | -0.06 ± 1.346 | — |
| Urea, Month 8 | 0.28 ± 1.131 | — |
| Urea, Month 12 | -0.11 ± 1.318 | — |
| Urea, Month 14 | -0.50 ± NA | — |
| Urea, Month 16 | 0.13 ± 1.444 | — |
| Urea, Month 20 | 0.17 ± 1.332 | — |
| Urea, Month 24 | 0.15 ± 1.474 | — |
| Urea, Month 26 | -0.92 ± 0.736 | — |
| Urea, Month 28 | -0.01 ± 1.628 | — |
| Urea, Month 30 | 0.17 ± 1.941 | — |
| Urea, Month 32 | 0.14 ± 1.419 | — |
| Urea, Month 34 | 0.50 ± 2.000 | — |
| Urea, Month 36 | 0.22 ± 1.393 | — |
| Urea, Month 38 | 1.00 ± 0.707 | — |
| Urea, Month 40 | 0.27 ± 1.390 | — |
| Urea, Month 42 | 0.25 ± 1.061 | — |
| Urea, Month 44 | 0.34 ± 1.475 | — |
| Urea, Month 46 | 0.63 ± 2.056 | — |
| Urea, Month 48 | 0.26 ± 1.266 | — |
| Urea, Month 50 | 0.50 ± 1.414 | — |
| Urea, Month 52 | -0.83 ± 1.211 | — |
| Urea, LTFU Month 1 | — | -0.80 ± 0.758 |
| Urea, LTFU Month 3 | — | 0.25 ± 0.866 |
| Urea, LTFU Month 6 | — | -1.08 ± 0.861 |
| Urea, LTFU Month 9 | — | -0.17 ± 1.291 |
| Urea, LTFU Month 12 | — | -0.30 ± 0.671 |
Blood samples were collected for the analysis of clinical chemistry parameters: carbon dioxide, chloride, glucose, phosphate, potassium, sodium and urea. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline was defined as post-dose visit value minus baseline value.
| Millimoles per liter | DTG + RPV |
|---|---|
| Carbon dioxide, Month 3 | -1.0 ± 1.53 |
| Carbon dioxide, Month 6 | -1.7 ± 1.50 |
| Carbon dioxide, Month 9 | -1.9 ± 2.85 |
| Carbon dioxide, Month 12 | -1.9 ± 2.48 |
| Chloride, Month 3 | 1.0 ± 1.83 |
| Chloride, Month 6 | 1.7 ± 2.14 |
| Chloride, Month 9 | 1.0 ± 0.82 |
| Chloride, Month 12 | 1.0 ± 2.08 |
| Glucose, Month 3 | 0.08 ± 0.259 |
| Glucose, Month 6 | 0.16 ± 0.483 |
| Glucose, Month 9 | 0.15 ± 0.700 |
| Glucose, Month 12 | 0.07 ± 0.55 |
| Phosphate, Month 3 | 0.02 ± 0.131 |
| Phosphate, Month 6 | 0.08 ± 0.177 |
| Phosphate, Month 9 | 0.05 ± 0.178 |
| Phosphate, Month 12 | -0.05 ± 0.101 |
| Potassium, Month 3 | -0.26 ± 0.378 |
| Potassium, Month 6 | -0.03 ± 0.250 |
| Potassium, Month 9 | 0.01 ± 0.135 |
| Potassium, Month 12 | -0.06 ± 0.257 |
| Sodium, Month 3 | 0.1 ± 1.68 |
| Sodium, Month 6 | -0.9 ± 0.90 |
| Sodium, Month 9 | -1.0 ± 2.58 |
| Sodium, Month 12 | -1.1 ± 1.07 |
| Urea, Month 3 | 1.43 ± 0.732 |
| Urea, Month 6 | 1.14 ± 1.144 |
| Urea, Month 9 | 1.86 ± 1.994 |
| Urea, Month 12 | 0.71 ± 0.756 |
Blood samples were collected for the analysis of clinical chemistry parameters: cholesterol, direct high density lipoprotein cholesterol, LDL cholesterol calculation, direct low density lipoprotein cholesterol and triglycerides. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline was defined as post-dose visit value minus baseline value.
| Millimoles per liter | CAB LA + RPV LA Q2M | LTFU: CAB LA+RPV LA Q2M Group |
|---|---|---|
| Cholesterol, Month 12 | 0.12 ± 0.760 | — |
| Cholesterol, Month 24 | 0.13 ± 0.849 | — |
| Cholesterol, Month 26 | 0.48 ± 0.569 | — |
| Cholesterol, Month 28 | 0.00 ± 0.906 | — |
| Cholesterol, Month 30 | 0.07 ± 1.378 | — |
| Cholesterol, Month 32 | -0.87 ± 0.601 | — |
| Cholesterol, Month 34 | 0.67 ± 1.378 | — |
| Cholesterol, Month 40 | -0.85 ± 0.804 | — |
| Cholesterol, Month 44 | 0.27 ± 0.106 | — |
| Cholesterol, Month 46 | -0.10 ± NA | — |
| Cholesterol, Month 48 | -0.15 ± 0.070 | — |
| Cholesterol, LTFU Month 1 | — | -0.87 ± 1.097 |
| Cholesterol, LTFU Month 12 | — | -0.68 ± 1.362 |
| Direct HDL cholesterol, Month 12 | -0.05 ± 0.224 | — |
| Direct HDL cholesterol, Month 24 | -0.02 ± 0.230 | — |
| Direct HDL cholesterol, Month 26 | -0.05 ± 0.154 | — |
| Direct HDL cholesterol, Month 28 | -0.05 ± 0.241 | — |
| Direct HDL cholesterol, Month 30 | 0.25 ± 0.141 | — |
| Direct HDL cholesterol, Month 32 | -0.20 ± 0.353 | — |
| Direct HDL cholesterol, Month 34 | -0.07 ± 0.247 | — |
| Direct HDL cholesterol, Month 40 | 0.08 ± 0.368 | — |
| Direct HDL cholesterol, Month 44 | -0.27 ± 0.247 | — |
| Direct HDL cholesterol, Month 46 | -0.35 ± NA | — |
| Direct HDL cholesterol, Month 48 | -0.20 ± 0.212 | — |
| Direct HDL cholesterol, LTFU Month 1 | — | -0.18 ± 0.213 |
| Direct HDL cholesterol, LTFU Month 12 | — | -0.04 ± 0.290 |
| LDL cholesterol calculation, Month 12 | 0.10 ± 0.718 | — |
| LDL cholesterol calculation, Month 24 | 0.14 ± 0.823 | — |
| LDL cholesterol calculation, Month 26 | 0.73 ± 0.613 | — |
| LDL cholesterol calculation, Month 28 | 0.06 ± 0.913 | — |
| LDL cholesterol calculation, Month 30 | 0.31 ± 2.128 | — |
| LDL cholesterol calculation, Month 32 | -0.30 ± 0.502 | — |
| LDL cholesterol calculation, Month 34 | 0.95 ± 1.286 | — |
| LDL cholesterol calculation, Month 40 | -0.91 ± 0.202 | — |
| LDL cholesterol calculation, Month 44 | -0.18 ± 0.530 | — |
| LDL cholesterol calculation, Month 46 | 0.05 ± NA | — |
| LDL cholesterol calculation, Month 48 | -0.03 ± 0.311 | — |
| LDL cholesterol calculation, LTFU Month 1 | — | -0.55 ± 0.989 |
| LDL cholesterol calculation, LTFU Month 12 | — | -0.34 ± 1.510 |
| Direct LDL cholesterol, Month 12 | 0.21 ± 0.367 | — |
| Direct LDL cholesterol, Month 24 | -0.23 ± NA | — |
| Triglycerides, Month 12 | 0.28 ± 1.965 | — |
| Triglycerides, Month 24 | 0.20 ± 1.071 | — |
| Triglycerides, Month 26 | -0.20 ± 0.888 | — |
| Triglycerides, Month 28 | -0.02 ± 0.705 | — |
| Triglycerides, Month 30 | -1.06 ± 1.329 | — |
| Triglycerides, Month 32 | -0.80 ± 0.989 | — |
| Triglycerides, Month 34 | -0.43 ± 0.353 | — |
| Triglycerides, Month 40 | -0.04 ± 1.724 | — |
| Triglycerides, Month 44 | 1.61 ± 0.834 | — |
| Triglycerides, Month 46 | 0.44 ± NA | — |
| Triglycerides, Month 48 | 0.18 ± 0.056 | — |
| Triglycerides, LTFU Month 1 | — | -0.29 ± 0.834 |
| Triglycerides, LTFU Month 12 | — | -0.64 ± 1.088 |
Blood samples were collected for the analysis of clinical chemistry parameters: cholesterol, HDL cholesterol direct, LDL cholesterol calculation, LDL cholesterol direct and triglycerides.
| Millimoles per liter | DTG + RPV |
|---|---|
| Cholesterol | 4.88 ± 1.352 |
| Direct HDL cholesterol | 1.59 ± 0.258 |
| LDL cholesterol calculation | 2.29 ± 0.52 |
| Direct LDL cholesterol | 4.45 ± NA |
| Triglycerides | 1.52 ± 1.493 |
Blood samples were collected for the analysis of clinical chemistry parameter: GFR from creatinine adjusted using CKD-EPI. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline was defined as post-dose visit value minus baseline value.
| Milliliter per minute per 1.73 meter^2 | CAB LA + RPV LA Q2M | LTFU: CAB LA+RPV LA Q2M Group |
|---|---|---|
| Month 2 | 1.9 ± 7.70 | — |
| Month 4 | 1.7 ± 10.09 | — |
| Month 6 | 1.4 ± 7.86 | — |
| Month 8 | 0.8 ± 8.63 | — |
| Month 12 | 0.4 ± 9.93 | — |
| Month 16 | -1.7 ± 10.06 | — |
| Month 20 | -0.2 ± 10.69 | — |
| Month 24 | -5.0 ± 11.01 | — |
| Month 26 | 1.8 ± 5.68 | — |
| Month 28 | -6.5 ± 9.44 | — |
| Month 30 | -12.3 ± 14.47 | — |
| Month 32 | -2.1 ± 9.71 | — |
| Month 34 | -0.5 ± 5.07 | — |
| Month 36 | -2.7 ± 10.12 | — |
| Month 38 | -8.0 ± NA | — |
| Month 40 | 0.8 ± 8.56 | — |
| Month 42 | -6.0 ± 7.94 | — |
| Month 44 | -1.9 ± 11.07 | — |
| Month 46 | -8.5 ± 7.78 | — |
| Month 48 | -2.8 ± 9.92 | — |
| Month 50 | 2.0 ± 7.07 | — |
| Month 52 | -0.5 ± 12.85 | — |
| LTFU Month 1 | — | -1.2 ± 9.26 |
| LTFU Month 3 | — | -14.3 ± 10.63 |
| LTFU Month 6 | — | -10.0 ± 14.62 |
| LTFU Month 9 | — | -8.8 ± 9.87 |
| LTFU Month 12 | — | -11.0 ± 7.11 |
Blood samples were collected for the analysis of clinical chemistry parameter: GFR from creatinine adjusted using CKD-EPI. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline was defined as post-dose visit value minus baseline value.
| Milliliter per minute per 1.73 meter^2 | DTG + RPV |
|---|---|
| Month 3 | -11.7 ± 10.83 |
| Month 6 | -7.4 ± 4.28 |
| Month 9 | -16.6 ± 12.27 |
| Month 12 | -7.3 ± 8.71 |
Blood samples were collected for the analysis of clinical chemistry parameter: GFR from creatinine adjusted for BSA. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline was defined as post-dose visit value minus baseline value.
| Milliliter per second per 1.73 meter^2 | CAB LA + RPV LA Q2M | LTFU: CAB LA+RPV LA Q2M Group |
|---|---|---|
| Month 2 | 0.03 ± 0.128 | — |
| Month 4 | 0.02 ± 0.168 | — |
| Month 8 | 0.01 ± 0.143 | — |
| Month 12 | 0.00 ± 0.165 | — |
| Month 16 | -0.02 ± 0.167 | — |
| Month 20 | 0.00 ± 0.178 | — |
| Month 24 | -0.08 ± 0.183 | — |
| Month 26 | 0.02 ± 0.094 | — |
| Month 28 | -0.10 ± 0.157 | — |
| Month 30 | -0.20 ± 0.241 | — |
| Month 32 | -0.03 ± 0.161 | — |
| Month 34 | 0.00 ± 0.084 | — |
| Month 36 | -0.04 ± 0.168 | — |
| Month 38 | -0.13 ± NA | — |
| Month 40 | 0.01 ± 0.142 | — |
| Month 42 | -0.10 ± 0.132 | — |
| Month 44 | -0.03 ± 0.184 | — |
| Month 46 | -0.14 ± 0.129 | — |
| Month 48 | -0.04 ± 0.165 | — |
| Month 50 | 0.03 ± 0.117 | — |
| Month 52 | 0.00 ± 0.214 | — |
| LTFU Month 1 | — | -0.02 ± 0.154 |
| LTFU Month 3 | — | -0.23 ± 0.177 |
| LTFU Month 6 | — | -0.16 ± 0.243 |
| LTFU Month 9 | — | -0.14 ± 0.164 |
| LTFU Month 12 | — | -0.18 ± 0.118 |
Blood samples were collected for the analysis of clinical chemistry parameter: GFR from creatinine adjusted for BSA. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline was defined as post-dose visit value minus baseline value.
| Milliliter per second per 1.73 meter^2 | DTG + RPV |
|---|---|
| Month 3 | -0.19 ± 0.180 |
| Month 6 | -0.12 ± 0.071 |
| Month 9 | -0.27 ± 0.204 |
| Month 12 | -0.12 ± 0.145 |
Blood samples were collected for the analysis of clinical chemistry parameter: lipase. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline was defined as post-dose visit value minus baseline value.
| Units per liter | CAB LA + RPV LA Q2M | LTFU: CAB LA+RPV LA Q2M Group |
|---|---|---|
| Month 2 | -0.1 ± 29.11 | — |
| Month 4 | 3.7 ± 47.68 | — |
| Month 6 | 24.5 ± 64.27 | — |
| Month 8 | -1.3 ± 29.43 | — |
| Month 12 | -2.9 ± 36.83 | — |
| Month 16 | -6.4 ± 31.83 | — |
| Month 20 | -4.0 ± 32.29 | — |
| Month 24 | -2.0 ± 34.89 | — |
| Month 26 | 11.0 ± 4.55 | — |
| Month 28 | -1.9 ± 26.19 | — |
| Month 30 | -1.0 ± 14.14 | — |
| Month 32 | 5.5 ± 56.93 | — |
| Month 34 | -12.8 ± 45.17 | — |
| Month 36 | 4.9 ± 51.90 | — |
| Month 38 | 20.0 ± NA | — |
| Month 40 | 0.7 ± 41.09 | — |
| Month 42 | -12.7 ± 27.39 | — |
| Month 44 | 5.6 ± 40.12 | — |
| Month 46 | -33.3 ± 118.26 | — |
| Month 48 | 3.7 ± 31.55 | — |
| Month 50 | -3.0 ± 28.28 | — |
| Month 52 | 3.2 ± 12.24 | — |
| LTFU Month 1 | — | 27.4 ± 48.97 |
| LTFU Month 3 | — | 1.5 ± 10.60 |
| LTFU Month 6 | — | 10.8 ± 30.53 |
| LTFU Month 9 | — | 3.7 ± 9.40 |
| LTFU Month 12 | — | 5.2 ± 6.38 |
Blood samples were collected for the analysis of clinical chemistry parameter: lipase. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline was defined as post-dose visit value minus baseline value.
| Units per liter | DTG + RPV |
|---|---|
| Month 3 | 2.6 ± 6.90 |
| Month 6 | 4.4 ± 4.35 |
| Month 9 | 1.3 ± 6.85 |
| Month 12 | 26.0 ± 49.76 |
Blood samples were collected for the analysis of clinical chemistry parameter: total cholesterol/ HDL cholesterol ratio. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline was defined as post-dose visit value minus baseline value.
| Total Cholesterol/HDL Cholesterol Ratio | CAB LA + RPV LA Q2M | LTFU: CAB LA+RPV LA Q2M Group |
|---|---|---|
| Month 12 | 0.20 ± 1.698 | — |
| Month 24 | 0.05 ± 1.279 | — |
| Month 26 | 0.55 ± 0.861 | — |
| Month 28 | 0.11 ± 1.153 | — |
| Month 30 | -1.01 ± 1.630 | — |
| Month 32 | -0.48 ± 1.191 | — |
| Month 34 | 0.43 ± 0.425 | — |
| Month 40 | -1.09 ± 1.390 | — |
| Month 44 | 1.65 ± 0.640 | — |
| Month 46 | 1.37 ± NA | — |
| Month 48 | 0.30 ± 0.434 | — |
| LTFU Month 1 | — | -0.28 ± 0.916 |
| LTFU Month 12 | — | -0.51 ± 1.078 |
Blood samples were collected for the analysis of clinical chemistry parameter: total cholesterol/ HDL cholesterol ratio. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline was defined as post-dose visit value minus baseline value.
| Total Cholesterol/HDL Cholesterol Ratio | DTG + RPV |
|---|---|
| Change From Baseline in Clinical Chemistry Parameter: Total Cholesterol/ HDL Cholesterol Ratio for DTG + RPV Arm at Month 6 [Maintenance Phase] | 0.55 ± 0.679 |
Blood samples were collected for the analysis of hematology parameters: basophils, eosinophils, leukocytes, lymphocytes, monocytes, neutrophils and platelets. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline was defined as post-dose visit value minus baseline value.
| 10^9 cells per liter | CAB LA + RPV LA Q2M | LTFU: CAB LA+RPV LA Q2M Group |
|---|---|---|
| Basophils, Month 2 | -0.000 ± 0.02200 | — |
| Basophils, Month 4 | 0.009 ± 0.02913 | — |
| Basophils, Month 8 | 0.003 ± 0.02524 | — |
| Basophils, Month 12 | -0.003 ± 0.02501 | — |
| Basophils, Month 16 | 0.003 ± 0.02629 | — |
| Basophils, Month 20 | 0.003 ± 0.02751 | — |
| Basophils, Month 22 | -0.020 ± 0.04243 | — |
| Basophils, Month 24 | 0.001 ± 0.02306 | — |
| Basophils, Month 26 | -0.004 ± 0.01673 | — |
| Basophils, Month 28 | 0.008 ± 0.02919 | — |
| Basophils, Month 30 | 0.007 ± 0.03862 | — |
| Basophils, Month 32 | 0.003 ± 0.02567 | — |
| Basophils, Month 34 | -0.010 ± 0.01000 | — |
| Basophils, Month 36 | -0.001 ± 0.03325 | — |
| Basophils, Month 38 | 0.000 ± 0.01414 | — |
| Basophils, Month 40 | 0.004 ± 0.02461 | — |
| Basophils, Month 42 | 0.000 ± 0.03606 | — |
| Basophils, Month 44 | -0.001 ± 0.02271 | — |
| Basophils, Month 46 | 0.005 ± 0.02121 | — |
| Basophils, Month 48 | -0.002 ± 0.02682 | — |
| Basophils, Month 50 | -0.045 ± 0.04950 | — |
| Basophils, Month 52 | 0.021 ± 0.02858 | — |
| Basophils, LTFU Month 1 | — | 0.004 ± 0.02702 |
| Basophils, LTFU Month 3 | — | 0.000 ± 0.02944 |
| Basophils, LTFU Month 6 | — | -0.001 ± 0.03764 |
| Basophils, LTFU Month 9 | — | 0.000 ± 0.02000 |
| Basophils, LTFU Month 12 | — | 0.010 ± 0.03240 |
| Eosinophils, Month 2 | 0.017 ± 0.11886 | — |
| Eosinophils, Month 4 | 0.004 ± 0.12341 | — |
| Eosinophils, Month 8 | 0.003 ± 0.14555 | — |
| Eosinophils, Month 12 | -0.000 ± 0.13671 | — |
| Eosinophils, Month 16 | -0.002 ± 0.12115 | — |
| Eosinophils, Month 20 | -0.004 ± 0.11308 | — |
| Eosinophils, Month 22 | 0.005 ± 0.00707 | — |
| Eosinophils, Month 24 | -0.021 ± 0.10959 | — |
| Eosinophils, Month 26 | 0.014 ± 0.04393 | — |
| Eosinophils, Month 28 | -0.021 ± 0.12165 | — |
| Eosinophils, Month 30 | 0.072 ± 0.09878 | — |
| Eosinophils, Month 32 | -0.009 ± 0.15093 | — |
| Eosinophils, Month 34 | 0.083 ± 0.11846 | — |
| Eosinophils, Month 36 | -0.020 ± 0.13447 | — |
| Eosinophils, Month 38 | 0.070 ± 0.21213 | — |
| Eosinophils, Month 40 | -0.014 ± 0.14536 | — |
| Eosinophils, Month 42 | 0.146 ± 0.04933 | — |
| Eosinophils, Month 44 | -0.023 ± 0.12973 | — |
| Eosinophils, Month 46 | 0.065 ± 0.02121 | — |
| Eosinophils, Month 48 | -0.016 ± 0.13128 | — |
| Eosinophils, Month 50 | -0.085 ± 0.19092 | — |
| Eosinophils, Month 52 | -0.020 ± 0.09675 | — |
| Eosinophils, LTFU Month 1 | — | -0.006 ± 0.03847 |
| Eosinophils, LTFU Month 3 | — | -0.042 ± 0.02062 |
| Eosinophils, LTFU Month 6 | — | 0.015 ± 0.05925 |
| Eosinophils, LTFU Month 9 | — | -0.041 ± 0.04535 |
| Eosinophils, LTFU Month 12 | — | 0.036 ± 0.04930 |
| Leukocytes, Month 2 | -0.054 ± 1.1875 | — |
| Leukocytes, Month 4 | 0.276 ± 1.4416 | — |
| Leukocytes, Month 8 | 0.257 ± 1.4252 | — |
| Leukocytes, Month 12 | -0.153 ± 1.1961 | — |
| Leukocytes, Month 16 | 0.333 ± 1.4322 | — |
| Leukocytes, Month 20 | 0.069 ± 1.2588 | — |
| Leukocytes, Month 22 | -0.050 ± 0.4950 | — |
| Leukocytes, Month 24 | 0.247 ± 1.3444 | — |
| Leukocytes, Month 26 | -0.700 ± 0.9220 | — |
| Leukocytes, Month 28 | 0.369 ± 1.2534 | — |
| Leukocytes, Month 30 | 0.775 ± 1.1147 | — |
| Leukocytes, Month 32 | 0.582 ± 1.5079 | — |
| Leukocytes, Month 34 | -0.033 ± 0.6351 | — |
| Leukocytes, Month 36 | 0.197 ± 1.3119 | — |
| Leukocytes, Month 38 | 0.450 ± 2.3335 | — |
| Leukocytes, Month 40 | 0.111 ± 1.4863 | — |
| Leukocytes, Month 42 | 0.750 ± 1.6299 | — |
| Leukocytes, Month 44 | 0.016 ± 1.4332 | — |
| Leukocytes, Month 46 | 0.700 ± 0.2828 | — |
| Leukocytes, Month 48 | 0.237 ± 1.3630 | — |
| Leukocytes, Month 50 | -2.650 ± 1.2021 | — |
| Leukocytes, Month 52 | 0.950 ± 0.6804 | — |
| Leukocytes, LTFU Month 1 | — | 0.740 ± 1.1327 |
| Leukocytes, LTFU Month 3 | — | 1.100 ± 1.4720 |
| Leukocytes, LTFU Month 6 | — | -0.067 ± 1.0820 |
| Leukocytes, LTFU Month 9 | — | -0.317 ± 0.5529 |
| Leukocytes, LTFU Month 12 | — | -0.240 ± 0.7369 |
| Lymphocytes, Month 2 | 0.116 ± 0.44032 | — |
| Lymphocytes, Month 4 | 0.150 ± 0.42751 | — |
| Lymphocytes, Month 8 | 0.100 ± 0.49306 | — |
| Lymphocytes, Month 12 | 0.022 ± 0.61142 | — |
| Lymphocytes, Month 16 | 0.144 ± 0.50914 | — |
| Lymphocytes, Month 20 | 0.197 ± 0.49264 | — |
| Lymphocytes, Month 22 | 0.815 ± 0.82731 | — |
| Lymphocytes, Month 24 | 0.184 ± 0.53796 | — |
| Lymphocytes, Month 26 | 0.064 ± 0.30262 | — |
| Lymphocytes, Month 28 | 0.269 ± 0.50159 | — |
| Lymphocytes, Month 30 | 0.657 ± 0.34219 | — |
| Lymphocytes, Month 32 | 0.294 ± 0.54583 | — |
| Lymphocytes, Month 34 | 0.260 ± 0.58813 | — |
| Lymphocytes, Month 36 | 0.176 ± 0.53181 | — |
| Lymphocytes, Month 38 | 0.185 ± 0.71418 | — |
| Lymphocytes, Month 40 | 0.193 ± 0.51843 | — |
| Lymphocytes, Month 42 | 0.990 ± 0.23388 | — |
| Lymphocytes, Month 44 | 0.090 ± 0.55940 | — |
| Lymphocytes, Month 46 | -0.375 ± 0.86974 | — |
| Lymphocytes, Month 48 | 0.225 ± 0.55785 | — |
| Lymphocytes, Month 50 | -0.765 ± 0.54447 | — |
| Lymphocytes, Month 52 | 0.580 ± 0.26967 | — |
| Lymphocytes, LTFU Month 1 | — | 0.316 ± 0.68995 |
| Lymphocytes, LTFU Month 3 | — | 0.215 ± 0.31268 |
| Lymphocytes, LTFU Month 6 | — | 0.018 ± 0.40276 |
| Lymphocytes, LTFU Month 9 | — | -0.013 ± 0.33339 |
| Lymphocytes, LTFU Month 12 | — | 0.182 ± 0.43906 |
| Monocytes, Month 2 | 0.022 ± 0.11715 | — |
| Monocytes, Month 4 | 0.048 ± 0.14689 | — |
| Monocytes, Month 8 | 0.026 ± 0.16979 | — |
| Monocytes, Month 12 | -0.021 ± 0.15241 | — |
| Monocytes, Month 16 | 0.060 ± 0.14219 | — |
| Monocytes, Month 20 | 0.032 ± 0.15386 | — |
| Monocytes, Month 22 | 0.060 ± 0.11314 | — |
| Monocytes, Month 24 | 0.039 ± 0.15115 | — |
| Monocytes, Month 26 | -0.012 ± 0.08585 | — |
| Monocytes, Month 28 | 0.093 ± 0.15913 | — |
| Monocytes, Month 30 | 0.105 ± 0.11328 | — |
| Monocytes, Month 32 | 0.030 ± 0.13926 | — |
| Monocytes, Month 34 | -0.060 ± 0.06557 | — |
| Monocytes, Month 36 | 0.016 ± 0.16850 | — |
| Monocytes, Month 38 | 0.195 ± 0.12021 | — |
| Monocytes, Month 40 | 0.037 ± 0.17293 | — |
| Monocytes, Month 42 | 0.230 ± 0.11358 | — |
| Monocytes, Month 44 | 0.003 ± 0.14568 | — |
| Monocytes, Month 46 | 0.020 ± 0.08485 | — |
| Monocytes, Month 48 | 0.026 ± 0.13077 | — |
| Monocytes, Month 50 | -0.085 ± 0.23335 | — |
| Monocytes, Month 52 | 0.198 ± 0.13556 | — |
| Monocytes, LTFU Month 1 | — | -0.020 ± 0.06245 |
| Monocytes, LTFU Month 3 | — | -0.007 ± 0.13451 |
| Monocytes, LTFU Month 6 | — | 0.038 ± 0.09621 |
| Monocytes, LTFU Month 9 | — | -0.031 ± 0.09283 |
| Monocytes, LTFU Month 12 | — | 0.008 ± 0.05541 |
| Neutrophils, Month 2 | -0.197 ± 0.99349 | — |
| Neutrophils, Month 4 | 0.056 ± 1.19574 | — |
| Neutrophils, Month 8 | 0.120 ± 1.18605 | — |
| Neutrophils, Month 12 | -0.134 ± 1.03311 | — |
| Neutrophils, Month 16 | 0.129 ± 1.23997 | — |
| Neutrophils, Month 20 | -0.158 ± 1.09672 | — |
| Neutrophils, Month 22 | -0.890 ± 1.14551 | — |
| Neutrophils, Month 24 | 0.019 ± 1.06166 | — |
| Neutrophils, Month 26 | -0.788 ± 0.92394 | — |
| Neutrophils, Month 28 | 0.025 ± 1.10870 | — |
| Neutrophils, Month 30 | -0.065 ± 0.70174 | — |
| Neutrophils, Month 32 | 0.265 ± 1.45710 | — |
| Neutrophils, Month 34 | -0.310 ± 0.32187 | — |
| Neutrophils, Month 36 | 0.027 ± 1.15025 | — |
| Neutrophils, Month 38 | -0.005 ± 1.70413 | — |
| Neutrophils, Month 40 | -0.100 ± 1.23231 | — |
| Neutrophils, Month 42 | 0.000 ± 1.35532 | — |
| Neutrophils, Month 44 | -0.049 ± 1.19998 | — |
| Neutrophils, Month 46 | 1.015 ± 1.30815 | — |
| Neutrophils, Month 48 | 0.005 ± 1.16199 | — |
| Neutrophils, Month 50 | -1.665 ± 1.26572 | — |
| Neutrophils, Month 52 | 0.151 ± 0.58952 | — |
| Neutrophils, LTFU Month 1 | — | 0.448 ± 0.47694 |
| Neutrophils, LTFU Month 3 | — | 0.932 ± 1.35866 |
| Neutrophils, LTFU Month 6 | — | -0.148 ± 0.90442 |
| Neutrophils, LTFU Month 9 | — | -0.238 ± 0.37408 |
| Neutrophils, LTFU Month 12 | — | -0.462 ± 0.51611 |
| Platelets, Month 2 | 3.77 ± 23.389 | — |
| Platelets, Month 4 | 5.40 ± 30.889 | — |
| Platelets, Month 8 | 3.74 ± 24.695 | — |
| Platelets, Month 12 | 1.14 ± 32.005 | — |
| Platelets, Month 16 | 8.37 ± 34.613 | — |
| Platelets, Month 20 | 4.19 ± 33.235 | — |
| Platelets, Month 22 | -10.50 ± 24.749 | — |
| Platelets, Month 24 | 5.36 ± 29.747 | — |
| Platelets, Month 26 | 31.00 ± 34.728 | — |
| Platelets, Month 28 | 7.05 ± 36.502 | — |
| Platelets, Month 30 | 10.00 ± 41.873 | — |
| Platelets, Month 32 | 16.29 ± 43.183 | — |
| Platelets, Month 34 | 24.67 ± 28.024 | — |
| Platelets, Month 36 | 18.09 ± 40.388 | — |
| Platelets, Month 38 | 9.50 ± 38.891 | — |
| Platelets, Month 40 | 12.52 ± 33.756 | — |
| Platelets, Month 42 | 18.50 ± 9.434 | — |
| Platelets, Month 44 | 21.07 ± 40.846 | — |
| Platelets, Month 46 | 28.50 ± 14.849 | — |
| Platelets, Month 48 | 16.70 ± 38.627 | — |
| Platelets, Month 50 | -2.50 ± 7.778 | — |
| Platelets, Month 52 | 22.50 ± 54.357 | — |
| Platelets, LTFU Month 1 | — | 10.80 ± 25.762 |
| Platelets, LTFU Month 3 | — | 7.25 ± 19.973 |
| Platelets, LTFU Month 6 | — | -8.00 ± 24.503 |
| Platelets, LTFU Month 9 | — | -13.50 ± 37.877 |
| Platelets, LTFU Month 12 | — | 0.80 ± 22.709 |
Blood samples were collected for the analysis of hematology parameters: basophils, eosinophils, leukocytes, lymphocytes, monocytes, neutrophils and platelets. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline was defined as post-dose visit value minus baseline value.
| 10^9 cells per liter | DTG + RPV |
|---|---|
| Basophils, Month 3 | -0.008 ± 0.01464 |
| Basophils, Month 6 | -0.010 ± 0.02309 |
| Basophils, Month 9 | -0.005 ± 0.01512 |
| Basophils, Month 12 | -0.010 ± 0.01732 |
| Eosinophils, Month 3 | -0.072 ± 0.16307 |
| Eosinophils, Month 6 | -0.057 ± 0.11236 |
| Eosinophils, Month 9 | -0.051 ± 0.10040 |
| Eosinophils, Month 12 | -0.030 ± 0.17127 |
| Leukocytes, Month 3 | 0.014 ± 0.7669 |
| Leukocytes, Month 6 | -0.386 ± 0.8355 |
| Leukocytes, Month 9 | 0.014 ± 1.3508 |
| Leukocytes, Month 12 | -0.057 ± 0.9343 |
| Lymphocytes, Month 3 | 0.053 ± 0.43811 |
| Lymphocytes, Month 6 | -0.019 ± 0.35435 |
| Lymphocytes, Month 9 | 0.085 ± 0.59379 |
| Lymphocytes, Month 12 | -0.001 ± 0.39121 |
| Monocytes, Month 3 | 0.098 ± 0.08877 |
| Monocytes, Month 6 | 0.020 ± 0.07211 |
| Monocytes, Month 9 | -0.021 ± 0.06644 |
| Monocytes, Month 12 | 0.004 ± 0.07435 |
| Neutrophils, Month 3 | 0.097 ± 0.47612 |
| Neutrophils, Month 6 | -0.295 ± 0.64143 |
| Neutrophils, Month 9 | 0.115 ± 1.20803 |
| Neutrophils, Month 12 | -0.034 ± 0.80715 |
| Platelets, Month 3 | -1.00 ± 18.841 |
| Platelets, Month 6 | -12.57 ± 35.298 |
| Platelets, Month 9 | -21.29 ± 61.372 |
| Platelets, Month 12 | -2.86 ± 47.544 |
Blood samples were collected for the analysis of hematology parameter: erythrocytes mean corpuscular volume. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline was defined as post-dose visit value minus baseline value.
| Femtoliters | CAB LA + RPV LA Q2M | LTFU: CAB LA+RPV LA Q2M Group |
|---|---|---|
| Month 2 | -1.07 ± 1.731 | — |
| Month 4 | -2.04 ± 2.186 | — |
| Month 8 | -1.42 ± 2.527 | — |
| Month 12 | -1.28 ± 2.528 | — |
| Month 16 | -2.91 ± 2.379 | — |
| Month 20 | -1.93 ± 2.544 | — |
| Month 22 | 2.00 ± 4.243 | — |
| Month 24 | -1.35 ± 2.985 | — |
| Month 26 | -2.60 ± 0.894 | — |
| Month 28 | -3.18 ± 2.918 | — |
| Month 30 | -6.75 ± 2.500 | — |
| Month 32 | -2.77 ± 3.355 | — |
| Month 34 | -3.67 ± 3.512 | — |
| Month 36 | -1.78 ± 2.592 | — |
| Month 38 | -1.50 ± 0.707 | — |
| Month 40 | -3.71 ± 3.217 | — |
| Month 42 | -6.75 ± 2.630 | — |
| Month 44 | -2.84 ± 3.167 | — |
| Month 46 | 0.50 ± 2.121 | — |
| Month 48 | -2.30 ± 3.339 | — |
| Month 50 | -1.00 ± 2.828 | — |
| Month 52 | -4.00 ± 3.847 | — |
| LTFU Month 1 | — | -3.20 ± 3.962 |
| LTFU Month 3 | — | -4.00 ± 3.742 |
| LTFU Month 6 | — | -0.83 ± 4.167 |
| LTFU Month 9 | — | -1.33 ± 4.457 |
| LTFU Month 12 | — | -1.60 ± 6.504 |
Blood samples were collected for the analysis of hematology parameter: erythrocytes mean corpuscular volume. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline was defined as post-dose visit value minus baseline value.
| Femtoliters | DTG + RPV |
|---|---|
| Month 3 | -1.00 ± 1.000 |
| Month 6 | 0.14 ± 1.574 |
| Month 9 | 0.29 ± 1.704 |
| Month 12 | -0.14 ± 1.952 |
Blood samples were collected for the analysis of hematology parameter: erythrocytes. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline was defined as post-dose visit value minus baseline value. SD=0.0000 is defined as SD resulted below the detectable limit of the assay and approximate to 0.0000.
| 10^12 cells per liter | CAB LA + RPV LA Q2M | LTFU: CAB LA+RPV LA Q2M Group |
|---|---|---|
| Month 2 | -0.064 ± 0.2773 | — |
| Month 4 | -0.021 ± 0.3185 | — |
| Month 8 | -0.085 ± 0.3164 | — |
| Month 12 | -0.063 ± 0.3279 | — |
| Month 16 | -0.034 ± 0.3014 | — |
| Month 20 | -0.020 ± 0.2754 | — |
| Month 22 | -0.450 ± 0.0707 | — |
| Month 24 | -0.061 ± 0.3181 | — |
| Month 26 | 0.020 ± 0.1924 | — |
| Month 28 | -0.113 ± 0.2949 | — |
| Month 30 | -0.075 ± 0.0500 | — |
| Month 32 | -0.087 ± 0.3801 | — |
| Month 34 | -0.233 ± 0.1155 | — |
| Month 36 | -0.090 ± 0.3591 | — |
| Month 38 | -0.350 ± 0.3536 | — |
| Month 40 | -0.056 ± 0.3528 | — |
| Month 42 | 0.025 ± 0.4272 | — |
| Month 44 | -0.072 ± 0.4086 | — |
| Month 46 | -0.100 ± 0.1414 | — |
| Month 48 | -0.090 ± 0.3196 | — |
| Month 50 | -0.300 ± 0.0000 | — |
| Month 52 | -0.200 ± 0.5177 | — |
| LTFU Month 1 | — | -0.160 ± 0.2408 |
| LTFU Month 3 | — | 0.075 ± 0.2217 |
| LTFU Month 6 | — | -0.250 ± 0.2811 |
| LTFU Month 9 | — | -0.433 ± 0.2944 |
| LTFU Month 12 | — | -0.160 ± 0.4722 |
Blood samples were collected for the analysis of hematology parameter: erythrocytes. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline was defined as post-dose visit value minus baseline value.
| 10^12 cells per liter | DTG + RPV |
|---|---|
| Month 3 | -0.114 ± 0.1464 |
| Month 6 | -0.171 ± 0.1113 |
| Month 9 | -0.171 ± 0.1704 |
| Month 12 | -0.143 ± 0.0976 |
Blood samples were collected for the analysis of hematology parameter: hematocrit. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline was defined as post-dose visit value minus baseline value.
| Proportion of red blood cells in blood | CAB LA + RPV LA Q2M | LTFU: CAB LA+RPV LA Q2M Group |
|---|---|---|
| Month 2 | -0.011 ± 0.02762 | — |
| Month 4 | -0.012 ± 0.02935 | — |
| Month 8 | -0.015 ± 0.02809 | — |
| Month 12 | -0.011 ± 0.02760 | — |
| Month 16 | -0.017 ± 0.02824 | — |
| Month 20 | -0.011 ± 0.02731 | — |
| Month 22 | -0.032 ± 0.00707 | — |
| Month 24 | -0.012 ± 0.02668 | — |
| Month 26 | -0.010 ± 0.01723 | — |
| Month 28 | -0.026 ± 0.02663 | — |
| Month 30 | -0.040 ± 0.00822 | — |
| Month 32 | -0.022 ± 0.03499 | — |
| Month 34 | -0.037 ± 0.01442 | — |
| Month 36 | -0.017 ± 0.03340 | — |
| Month 38 | -0.034 ± 0.02192 | — |
| Month 40 | -0.023 ± 0.03088 | — |
| Month 42 | -0.025 ± 0.03938 | — |
| Month 44 | -0.021 ± 0.03702 | — |
| Month 46 | -0.006 ± 0.00353 | — |
| Month 48 | -0.019 ± 0.03114 | — |
| Month 50 | -0.033 ± 0.01697 | — |
| Month 52 | -0.041 ± 0.04229 | — |
| LTFU Month 1 | — | -0.028 ± 0.01864 |
| LTFU Month 3 | — | -0.012 ± 0.02102 |
| LTFU Month 6 | — | -0.027 ± 0.03065 |
| LTFU Month 9 | — | -0.044 ± 0.02265 |
| LTFU Month 12 | — | -0.022 ± 0.03928 |
Blood samples were collected for the analysis of hematology parameter: hematocrit. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline was defined as post-dose visit value minus baseline value.
| Proportion of red blood cells in blood | DTG + RPV |
|---|---|
| Month 3 | -0.015 ± 0.01516 |
| Month 6 | -0.013 ± 0.01287 |
| Month 9 | -0.013 ± 0.01332 |
| Month 12 | -0.013 ± 0.01491 |
Blood samples were collected for the analysis of hematology parameter: hemoglobin. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline was defined as post-dose visit value minus baseline value.
| Grams per liter | CAB LA + RPV LA Q2M | LTFU: CAB LA+RPV LA Q2M Group |
|---|---|---|
| Month 2 | -2.11 ± 8.801 | — |
| Month 4 | -1.57 ± 9.433 | — |
| Month 8 | -3.29 ± 8.542 | — |
| Month 12 | -3.19 ± 8.814 | — |
| Month 16 | -3.44 ± 8.293 | — |
| Month 20 | -2.30 ± 8.054 | — |
| Month 22 | -13.00 ± 1.414 | — |
| Month 24 | -3.35 ± 8.671 | — |
| Month 26 | 0.60 ± 6.804 | — |
| Month 28 | -4.06 ± 8.281 | — |
| Month 30 | -4.00 ± 4.243 | — |
| Month 32 | -4.13 ± 11.183 | — |
| Month 34 | -8.33 ± 3.215 | — |
| Month 36 | -4.86 ± 10.749 | — |
| Month 38 | -8.50 ± 6.364 | — |
| Month 40 | -4.51 ± 9.701 | — |
| Month 42 | -3.50 ± 11.358 | — |
| Month 44 | -6.27 ± 11.766 | — |
| Month 46 | -6.50 ± 2.121 | — |
| Month 48 | -7.41 ± 9.341 | — |
| Month 50 | -9.00 ± 9.899 | — |
| Month 52 | -6.67 ± 11.605 | — |
| LTFU Month 1 | — | -3.40 ± 7.956 |
| LTFU Month 3 | — | 1.50 ± 3.697 |
| LTFU Month 6 | — | -4.67 ± 9.993 |
| LTFU Month 9 | — | -10.00 ± 6.000 |
| LTFU Month 12 | — | -1.20 ± 14.464 |
Blood samples were collected for the analysis of hematology parameter: hemoglobin. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline was defined as post-dose visit value minus baseline value.
| Grams per liter | DTG + RPV |
|---|---|
| Month 3 | -3.57 ± 6.554 |
| Month 6 | -4.29 ± 2.928 |
| Month 9 | -4.86 ± 3.891 |
| Month 12 | -4.57 ± 5.062 |
Urine samples were collected for the analysis of urine albumin/creatinine ratio and urine protein/creatinine ratio.
| Ratio | CAB LA + RPV LA Q2M | DTG + RPV |
|---|---|---|
| Urine albumin/creatinine ratio | 0.7 ± 0.980 | 0.4 ± 0.122 |
| Urine protein/creatinine ratio | 7.6 ± 4.528 | 9.1 ± 7.237 |
Urine samples were collected for the analysis of urine creatinine.
| Micromoles per liter | CAB LA + RPV LA Q2M | DTG + RPV |
|---|---|---|
| Absolute Values of Urine Creatinine | 14875.6 ± 9267.95 | 12112.9 ± 7186.16 |
Urine samples were collected for the analysis of urine phosphate.
| Millimoles per liter | CAB LA + RPV LA Q2M | DTG + RPV |
|---|---|---|
| Absolute Values of Urine Phosphate | 18.2 ± 15.306 | 14.7 ± 6.917 |
Urine samples were collected for the analysis of urine specific gravity. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine.
| Ratio | CAB LA + RPV LA Q2M | DTG + RPV |
|---|---|---|
| Absolute Values of Urine Specific Gravity | 1.0 ± 0.007 | 1.0 ± 0.007 |
Urine samples were collected for analysis of urine pH. pH is calculated on a scale of 0 to 14, values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH of less than 7 is acidic and a pH of greater than 7 is basic. Normal urine has a slightly acidic pH (5.0-6.0).
| pH | CAB LA + RPV LA Q2M | DTG + RPV |
|---|---|---|
| Absolute Values of Urine Potential of Hydrogen (pH) | 6.1 ± 0.739 | 6.5 ± 0.345 |
Plasma samples were collected and analyzed for genotypic resistance from participants who met confirmed virologic withdrawal criteria.
| Participants | CAB LA + RPV LA Q2M | DTG + RPV |
|---|---|---|
| Number of Participants With Treatment Emergent Genotypic Resistance | 0 | — |
Plasma samples were collected and analyzed from participants who met confirmed virologic withdrawal criteria.
| Participants | CAB LA + RPV LA Q2M | DTG + RPV |
|---|---|---|
| Number of Participants With Treatment Emergent Phenotypic Resistance | 0 | — |
HIVDQoL includes 2 overview items and 26 domain items. The 2 overview items: Item 1: 3(excellent) to -3(extremely bad); Higher score indicates better quality of life. Item 2: -3(very much better) to 1(worse); Lower score indicates better quality of life. The Weighted Impact Score (WIS) was calculated for the 26 domain items by multiplying impact score(IS) (-3\[maximum {max.} negative impact\] to +1\[max. positive impact\] by the corresponding importance score (3 \[very important\] to 0\[not all important\]). Average Weighted Impact (AWI) score was calculated by summing individual weighted IS and dividing by the number of domain items. The ranges of WIS and average IS were from -9(max. negative) to +3(max. positive);higher score indicates positive impact. Change from Baseline was defined as post-dose visit value minus Baseline value (latest pre-treatment assessment with a non-missing value). SD=0.00 is defined as SD resulted below the detectable limit of the assay and approximate to 0.00.
| Scores on a scale | CAB LA + RPV LA Q2M | DTG + RPV |
|---|---|---|
| Overview Item 1, Month 6 | 0.1 ± 0.65 | 0.4 ± 0.53 |
| Overview Item 1, Month 12 | 0.0 ± 0.75 | -0.1 ± 0.38 |
| Overview Item 2, Month 6 | 0.0 ± 1.11 | 0.3 ± 1.25 |
| Overview Item 2, Month 12 | 0.2 ± 1.05 | -0.6 ± 1.13 |
| Leisure, Month 6 | 0.1 ± 2.20 | 0.9 ± 1.46 |
| Leisure, Month 12 | 0.2 ± 2.02 | -1.6 ± 3.74 |
| Work, Month 6 | -0.3 ± 2.07 | -0.9 ± 4.14 |
| Work, Month 12 | -0.1 ± 2.48 | -0.7 ± 2.75 |
| Holiday, Month 6 | -0.5 ± 2.24 | -0.3 ± 3.55 |
| Holiday, Month 12 | -0.1 ± 2.76 | -2.0 ± 2.83 |
| Getting out and about, Month 6 | 0.0 ± 1.83 | -1.1 ± 3.76 |
| Getting out and about, Month 12 | -0.2 ± 2.01 | -1.9 ± 2.48 |
| Long journey, Month 6 | 0.3 ± 2.24 | -0.4 ± 2.70 |
| Long journey, Month 12 | 0.4 ± 2.45 | -2.3 ± 2.93 |
| Do Physically, Month 6 | -0.2 ± 2.09 | -0.7 ± 2.36 |
| Do Physically, Month 12 | -0.3 ± 2.39 | -1.7 ± 2.63 |
| Family, Month 6 | -0.1 ± 1.38 | -0.9 ± 2.27 |
| Family, Month 12 | -0.3 ± 2.30 | -1.5 ± 2.51 |
| Friends, Month 6 | -0.7 ± 1.93 | -1.1 ± 2.85 |
| Friends, Month 12 | -0.3 ± 2.57 | -2.0 ± 2.38 |
| Go on dates, Month 6 | -0.4 ± 2.04 | -3.5 ± 3.54 |
| Go on dates, Month 12 | -0.2 ± 3.11 | -3.5 ± 3.54 |
| Close relationships, Month 6 | 0.4 ± 3.10 | -0.5 ± 2.95 |
| Close relationships, Month 12 | 0.2 ± 3.13 | -0.5 ± 2.95 |
| Sex life, Month 6 | 0.2 ± 2.74 | -1.3 ± 2.80 |
| Sex life, Month 12 | -0.2 ± 2.62 | -1.0 ± 3.00 |
| Physical appearance, Month 6 | -0.3 ± 1.78 | -1.1 ± 2.85 |
| Physical appearance, Month 12 | -0.2 ± 2.28 | -1.4 ± 2.23 |
| Self-confidence, Month 6 | 0.0 ± 2.35 | -1.7 ± 2.43 |
| Self-confidence, Month 12 | 0.2 ± 2.83 | -2.9 ± 3.48 |
| Motivation, Month 6 | -0.3 ± 2.04 | -0.6 ± 2.51 |
| Motivation, Month 12 | -0.3 ± 2.85 | -2.1 ± 2.85 |
| Stigma, Month 6 | -1.1 ± 2.38 | — |
| Stigma, Month 12 | 0.0 ± 3.03 | -2.0 ± NA |
| Conceal, Month 6 | -0.6 ± 2.91 | -1.6 ± 3.51 |
| Conceal, Month 12 | 0.3 ± 3.04 | -0.4 ± 4.10 |
| Feelings About the Future, Month 6 | 0.0 ± 2.89 | 1.0 ± 2.24 |
| Feelings About the Future, Month 12 | 0.3 ± 3.02 | -0.9 ± 2.85 |
| Financial Situation, Month 6 | -0.1 ± 2.76 | 1.1 ± 1.46 |
| Financial Situation, Month 12 | -0.1 ± 2.59 | -0.6 ± 4.61 |
| Depend on Others, Month 6 | -0.4 ± 3.11 | 0.0 ± 0.00 |
| Depend on Others, Month 12 | -0.2 ± 2.73 | -1.2 ± 3.25 |
| Others Fuss or Worry, Month 6 | 0.0 ± 3.00 | -1.6 ± 3.36 |
| Others Fuss or Worry, Month 12 | 0.1 ± 3.21 | -0.3 ± 3.50 |
| Freedom to Eat, Month 6 | 0.0 ± 1.98 | -1.3 ± 3.40 |
| Freedom to Eat, Month 12 | 0.1 ± 2.62 | -1.1 ± 2.48 |
| Freedom to Drink, Month 6 | -0.2 ± 1.81 | -0.7 ± 4.42 |
| Freedom to Drink, Month 12 | -0.1 ± 2.47 | -1.7 ± 3.40 |
| Spiritual/Religious Life, Month 6 | -0.1 ± 2.46 | -0.5 ± 1.22 |
| Spiritual/Religious Life, Month 12 | -0.1 ± 1.14 | -1.0 ± 2.45 |
| Feelings About the Past, Month 6 | -0.3 ± 2.69 | 0.7 ± 2.21 |
| Feelings About the Past, Month 12 | 0.0 ± 2.74 | -1.3 ± 2.21 |
| Having Children or More Children, Month 6 | 0.3 ± 1.86 | 1.3 ± 4.27 |
| Having Children or More Children, Month 12 | -0.3 ± 2.82 | -1.5 ± 3.00 |
| Sleep, Month 6 | -0.2 ± 2.32 | 0.7 ± 1.25 |
| Sleep, Month 12 | 0.0 ± 2.56 | -0.4 ± 2.70 |
| Average Weighted Impact, Month 6 | -0.17 ± 1.084 | -0.43 ± 1.792 |
| Average Weighted Impact, Month 12 | -0.07 ± 1.690 | -1.27 ± 1.695 |
HIVTSQs total treatment satisfaction score is computed with 1-11 items. Items 1-11 are summed to produce score with possible range of 0 to 66. Higher the score, greater improvement in satisfaction with treatment as compared to the past few weeks; lower score, greater the deterioration in satisfaction with treatment. A score of 0 represents no change. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from baseline was defined as post-dose visit value minus baseline value.
| Scores on a scale | CAB LA + RPV LA Q2M | DTG + RPV |
|---|---|---|
| Month 6 | -0.19 ± 6.419 | 0.71 ± 3.773 |
| Month 12 | -0.42 ± 6.659 | 0.14 ± 6.256 |
HIVTSQs is a 12 item questionnaire. The individual item scores are rated as 6 (very satisfied, convenient, flexible, etc.) to 0 (very dissatisfied, inconvenient, inflexible, etc.). Higher scores represent greater treatment satisfaction as compared to the past few weeks. Change from Baseline is defined as post-dose value minus Baseline value. Baseline value is defined as latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. SD=0.00 is defined as SD resulted below the detectable limit of the assay and approximate to 0.00.
| Scores on a scale | CAB LA + RPV LA Q2M | DTG + RPV |
|---|---|---|
| Item 1, Month 6 | -0.1 ± 0.82 | 0.0 ± 0.00 |
| Item 1, Month 12 | -0.1 ± 0.75 | -0.1 ± 0.38 |
| Item 2, Month 6 | -0.1 ± 0.46 | -0.3 ± 0.49 |
| Item 2, Month 12 | 0.0 ± 0.34 | -0.1 ± 0.38 |
| Item 3, Month 6 | -0.5 ± 1.41 | 0.1 ± 0.38 |
| Item 3, Month 12 | -0.5 ± 1.21 | -0.1 ± 0.38 |
| Item 4, Month 6 | 0.0 ± 0.95 | 0.0 ± 0.00 |
| Item 4, Month 12 | 0.1 ± 0.93 | 0.1 ± 0.69 |
| Item 5, Month 6 | 0.1 ± 1.00 | 0.3 ± 0.49 |
| Item 5, Month 12 | 0.1 ± 1.14 | 0.1 ± 0.38 |
| Item 6, Month 6 | 0.1 ± 1.13 | 0.4 ± 1.62 |
| Item 6, Month 12 | 0.0 ± 1.31 | 0.3 ± 1.80 |
| Item 7, Month 6 | 0.1 ± 0.74 | 0.0 ± 0.58 |
| Item 7, Month 12 | 0.0 ± 1.06 | 0.1 ± 0.69 |
| Item 8, Month 6 | 0.2 ± 0.93 | 0.0 ± 0.58 |
| Item 8, Month 12 | 0.1 ± 0.95 | 0.0 ± 0.58 |
| Item 9, Month 6 | -0.1 ± 0.61 | 0.0 ± 0.00 |
| Item 9, Month 12 | -0.2 ± 0.80 | -0.1 ± 0.38 |
| Item 10, Month 6 | 0.1 ± 0.91 | 0.3 ± 0.76 |
| Item 10, Month 12 | 0.1 ± 1.03 | 0.1 ± 0.90 |
| Item 11, Month 6 | 0.0 ± 1.09 | -0.1 ± 0.38 |
| Item 11, Month 12 | 0.1 ± 0.79 | -0.1 ± 0.90 |
| Item 12, Month 6 | -1.3 ± 1.59 | -0.6 ± 1.13 |
| Item 12, Month 12 | -1.1 ± 1.58 | -0.1 ± 0.38 |
HIVTSQc (change version) total treatment satisfaction score is computed with 1-11 items. Items 1-11 are summed to produce score with possible range:-33 to 33. Higher scores represent greater improvement in treatment satisfaction compared to satisfaction with treatment received during the induction phase; lower scores represented deterioration in satisfaction with treatment. A score of 0 represents no change. A maximum of 5 items can be missing, the missing scores were imputed with the mean of the completed item scores. If 6 or more items are missing, then the overall treatment satisfaction scale score was not computed and remained missing.
| Scores on a scale | CAB LA + RPV LA Q2M | DTG + RPV |
|---|---|---|
| Change in Treatment Satisfaction Over Time Using the HIV Treatment Satisfaction Change Questionnaire (HIVTSQc) | 28.0 ± 6.78 | 27.7 ± 6.97 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of CAB LA. This was a conditional secondary endpoint for which results are not available because the trough concentrations for this product are well characterized and therefore, secondary population pharmacokinetic (Pop PK) analyses were not conducted.
No measurements were reported for this outcome.
Blood samples were collected at indicated time points for pharmacokinetic analysis of RPV LA. This was a conditional secondary endpoint for which results are not available because the trough concentrations for this product are well characterized and therefore, secondary Pop PK analyses were not conducted.
No measurements were reported for this outcome.
Collected over Non-Serious adverse events (Other Adverse events (AEs)) and Serious adverse events (SAE) were collected from Day 1 and up to End of LTFU Phase (approximately up to 12 months after exiting the Maintenance Phase, up to a maximum of 52 months).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| CAB LA + RPV LA Q2M | 0/90 (0%) | 10/90 (11.1%) | 86/90 (95.6%) |
| DTG + RPV | 0/7 (0%) | 0/7 (0%) | 3/7 (42.9%) |
| LTFU: CAB LA+RPV LA Q2M Group | 0/6 (0%) | 0/6 (0%) | 0/6 (0%) |
| Event | CAB LA + RPV LA Q2M | DTG + RPV | LTFU: CAB LA+RPV LA Q2M Group |
|---|---|---|---|
| Cholecystitis acuteHepatobiliary disorders | 1/90 | 0/7 | 0/6 |
| CholelithiasisHepatobiliary disorders | 1/90 | 0/7 | 0/6 |
| Anal abscessInfections and infestations | 1/90 | 0/7 | 0/6 |
| OrchitisInfections and infestations | 1/90 | 0/7 | 0/6 |
| Urinary tract infection bacterialInfections and infestations | 1/90 | 0/7 | 0/6 |
| ProctitisGastrointestinal disorders | 1/90 | 0/7 | 0/6 |
| Injection site extravasationGeneral disorders | 1/90 | 0/7 | 0/6 |
| COVID-19 pneumoniaInfections and infestations | 1/90 | 0/7 | 0/6 |
| CellulitisInfections and infestations | 1/90 | 0/7 | 0/6 |
| Staphylococcal infectionInfections and infestations | 1/90 | 0/7 | 0/6 |
| Event | CAB LA + RPV LA Q2M | DTG + RPV | LTFU: CAB LA+RPV LA Q2M Group |
|---|---|---|---|
| Injection site painGeneral disorders | 67/90 | 0/7 | 0/6 |
| COVID-19Infections and infestations | 30/90 | 0/7 | 0/6 |
| Upper respiratory tract infectionInfections and infestations | 16/90 | 0/7 | 0/6 |
| PyrexiaGeneral disorders | 14/90 | 0/7 | 0/6 |
| NasopharyngitisInfections and infestations | 14/90 | 0/7 | 0/6 |
| Injection site discomfortGeneral disorders | 13/90 | 0/7 | 0/6 |
| SyphilisInfections and infestations | 13/90 | 0/7 | 0/6 |
| DiarrhoeaGastrointestinal disorders | 13/90 | 0/7 | 0/6 |
| Abdominal painGastrointestinal disorders | 2/90 | 1/7 | 0/6 |
| HeadacheNervous system disorders | 9/90 | 1/7 | 0/6 |
| Age, Continuous(Years) | CAB LA + RPV LA Q2M | DTG + RPV | Total |
|---|---|---|---|
| Overall Study | 41.2 ± 9.49 | 49.1 ± 11.42 | 41.7 ± 9.80 |
| Sex: Female, Male(Participants) | CAB LA + RPV LA Q2M | DTG + RPV | Total |
|---|---|---|---|
| Female | 2 | 0 | 2 |
| Male | 88 | 7 | 95 |
| Race/Ethnicity, Customized(Participants) | CAB LA + RPV LA Q2M | DTG + RPV | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian-Japanese/East Asian/South East Asian Heritage | 1 | 0 | 1 |
| Black or African American | 21 | 3 | 24 |
| White | 63 | 4 | 67 |
| Multiple | 4 | 0 | 4 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: IPD will be made available, within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.
Access criteria: Access is provided, after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided, for an initial period of 12 months but an extension can be granted, when justified for up to another 12 months.
Data sharing details ↗ · clinicalstudydatarequest.com
Ran from Sep 2018 to primary completion in Dec 2019, 14 months.
Results were first posted in Jan 2021, 1 year 1 month after primary completion.
Of 34 industry-sponsored phase 2 interventional studies under HIV Infections, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 31. This study's 14 months is below that.
Counting every sponsor, half of 99 studies reached it within 31 months; a quarter within 17 and three quarters within 58.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cabotegravir